<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Contemp Brachytherapy</journal-id><journal-id journal-id-type="iso-abbrev">J Contemp Brachytherapy</journal-id><journal-id journal-id-type="publisher-id">JCB</journal-id><journal-title-group><journal-title>Journal of Contemporary Brachytherapy</journal-title></journal-title-group><issn pub-type="ppub">1689-832X</issn><issn pub-type="epub">2081-2841</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23634153</article-id><article-id pub-id-type="pmc">3635047</article-id><article-id pub-id-type="publisher-id">20569</article-id><article-id pub-id-type="doi">10.5114/jcb.2013.34342</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Skowronek</surname><given-names>Janusz</given-names></name><degrees>MD, PhD, Asst. Prof.</degrees></contrib></contrib-group><aff>Brachytherapy Department, Greater Poland Cancer Center, Poznań, Poland</aff><aff>Electroradiology Department, Poznań University of Medical Sciences, Poznań, Poland</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Janusz Skowronek, MD, PhD, Asst. Prof., Brachytherapy Department, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznań, Poland. phone: +48 61 885 08 18. +48 602 618 538 (mobile). fax: +48 61 885 08 34. e-mail: <email xlink:href="janusz.skowronek@wco.pl">janusz.skowronek@wco.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>3</month><year>2013</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2013</year></pub-date><volume>5</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><history><date date-type="received"><day>06</day><month>12</month><year>2012</year></date><date date-type="rev-recd"><day>21</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Termedia</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="2958" xml_f="2965" txt_i="11" txt_f="18">Purpose</offsets></title><p><offsets xml_i="2976" xml_f="4701" txt_i="19" txt_f="1744">Permanent low-dose-rate (LDR-BT) and temporary high-dose-rate (HDR-BT) brachytherapy are competitive techniques for clinically localized prostate radiotherapy. Although a randomized trial will likely never to be conducted comparing these two forms of brachytherapy, a comparative analysis proves useful in understanding some of their intrinsic differences, several of which could be exploited to improve outcomes. The aim of this paper is to look for possible similarities and differences between both brachytherapy modalities. Indications and contraindications for monotherapy and for brachytherapy as a boost to external beam radiation therapy (EBRT) are presented. It is suggested that each of these techniques has attributes that advocates for one or the other. First, they represent the extreme ends of the spectrum with respect to dose rate and fractionation, and therefore have inherently different radiobiological properties. Low-dose-rate brachytherapy has the great advantage of being practically a one-time procedure, and enjoys a long-term follow-up database supporting its excellent outcomes and low morbidity. Low-dose-rate brachytherapy has been a gold standard for prostate brachytherapy in low risk patients since many years. On the other hand, HDR is a fairly invasive procedure requiring several sessions associated with a brief hospital stay. Although lacking in significant long-term data, it possesses the technical advantage of control over its postimplant dosimetry (by modulating the source dwell time and position), which is absent in LDR brachytherapy. This important difference in dosimetric control allows HDR doses to be escalated safely, a flexibility that does not exist for LDR brachytherapy.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4732" xml_f="4743" txt_i="1746" txt_f="1757">Conclusions</offsets></title><p><offsets xml_i="4754" xml_f="5103" txt_i="1758" txt_f="2107">Radiobiological models support the current clinical evidence for equivalent outcomes in localized prostate cancer with either LDR or HDR brachytherapy, using current dose regimens. At present, all available clinical data regarding these two techniques suggests that they are equally effective, stage for stage, in providing high tumor control rates.</offsets></p></sec></abstract><kwd-group><kwd>brachytherapy</kwd><kwd>HDR</kwd><kwd>LDR</kwd><kwd>prostate cancer</kwd><kwd>seeds</kwd></kwd-group></article-meta></front><body><sec id="S0001"><title><offsets xml_i="5293" xml_f="5300" txt_i="2116" txt_f="2123">Purpose</offsets></title><p><offsets xml_i="5311" xml_f="5729" txt_i="2124" txt_f="2542">Patients with organ-confined prostate cancer are the appropriate candidates for curative treatment. There are several modalities that can be performed in order to treat this kind of cancer, such as: external beam radiation therapy (EBRT), prostatectomy, cryotherapy or interstitial brachytherapy (BT). Brachytherapy is one of the oldest methods and means implantation of radioactive sources directly into the prostate.</offsets></p><sec id="S20002"><title><offsets xml_i="5757" xml_f="5784" txt_i="2543" txt_f="2570">Low-dose-rate brachytherapy</offsets></title><p><offsets xml_i="5795" xml_f="6414" txt_i="2571" txt_f="3190">Low-dose-rate brachytherapy is one of the radiation methods that is known for almost 30 years in treatment of localized prostate cancer. The main idea of this method is to implant small radioactive seeds as a source of radiation, directly into the prostate gland. Low-dose-rate brachytherapy is applied as a monotherapy, and also used along with EBRT as a boost. It is used as a sole radical treatment modality, however, not as a palliative treatment. The application of permanent seeds implants is a curative treatment alternative in patients with organ-confined cancer, without extracapsular extension of the tumour [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="6450" xml_f="6451" txt_i="3190" txt_f="3191">1</offsets></xref><offsets xml_i="6458" xml_f="6459" txt_i="3191" txt_f="3192">–</offsets><xref ref-type="bibr" rid="CIT0007"><offsets xml_i="6495" xml_f="6496" txt_i="3192" txt_f="3193">7</offsets></xref><offsets xml_i="6503" xml_f="6589" txt_i="3193" txt_f="3279">]. Recommendations are based on risk groups which are confirmed by several societies (</offsets><xref ref-type="table" rid="T0001"><offsets xml_i="6624" xml_f="6632" txt_i="3279" txt_f="3287">Tables 1</offsets></xref><offsets xml_i="6639" xml_f="6644" txt_i="3287" txt_f="3292"> and </offsets><xref ref-type="table" rid="T0002"><offsets xml_i="6679" xml_f="6680" txt_i="3292" txt_f="3293">2</offsets></xref><offsets xml_i="6687" xml_f="6690" txt_i="3293" txt_f="3296">) [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="6726" xml_f="6727" txt_i="3296" txt_f="3297">1</offsets></xref><offsets xml_i="6734" xml_f="6736" txt_i="3297" txt_f="3299">, </offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="6772" xml_f="6773" txt_i="3299" txt_f="3300">4</offsets></xref><offsets xml_i="6780" xml_f="6782" txt_i="3300" txt_f="3302">, </offsets><xref ref-type="bibr" rid="CIT0008"><offsets xml_i="6818" xml_f="6819" txt_i="3302" txt_f="3303">8</offsets></xref><offsets xml_i="6826" xml_f="7391" txt_i="3303" txt_f="3868">]. This technique is particular favorite in United States, Japan, Netherlands, Spain. In Eastern European countries, however, high-dose rate brachytherapy method (HDR-BT) is still more popular in early staged prostate cancer treatment. As a monotherapy, LDR-BT seems to be a reliable choice for early stage prostate cancer, according to low morbidity rate good results and short hospitalization. It is curative alternative of radical prostatectomy or EBRT (i.e. 3D CRT, IMRT) with comparable long-term survival and biochemical control, and most favorable toxicity [</offsets><xref ref-type="bibr" rid="CIT0009"><offsets xml_i="7427" xml_f="7428" txt_i="3868" txt_f="3869">9</offsets></xref><offsets xml_i="7435" xml_f="7436" txt_i="3869" txt_f="3870">–</offsets><xref ref-type="bibr" rid="CIT0014"><offsets xml_i="7472" xml_f="7474" txt_i="3870" txt_f="3872">14</offsets></xref><offsets xml_i="7481" xml_f="8696" txt_i="3872" txt_f="5087">]. Low-dose-rate brachytherapy represents the most conformal radiation therapy, and the number of patients referred to this radical treatment has grown rapidly in last 15 years, especially in the United States. In 1995, brachytherapy has taken a part in prostate cancer treatment only in ∼5% (surgery ∼65% procedures). Development of new techniques with new computer planning systems caused raising popularity of brachytherapy to about 40% in 2006. There are several reasons why LDR-BT achieved such popularity. Better toxicity profile with higher dose applying to prostate gland are the main points for brachytherapy in comparison with EBRT. Comparing with radical prostatectomy, permanent seed's implantation is a short, one day therapy with lower complication rate during and after the procedure (bleeding, urinary incontinence, impotence). Specific selection of radioactive isotopes and their correct localization, allows to deposit high dose into the prostate tumor with rapid fall off the dose outside the area of treatment, and – at the same time – allows to preserve organs at risk (OaRs). Low-dose-rate brachytherapy has been a gold standard for prostate brachytherapy in low risk patients for many years.
</offsets></p><table-wrap id="T0001" position="float"><label><offsets xml_i="8747" xml_f="8754" txt_i="5088" txt_f="5095">Table 1</offsets></label><caption><p><offsets xml_i="8774" xml_f="8852" txt_i="5095" txt_f="5173">American Brachytherapy Society recommendations for LDR-BT of prostate cancer [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="8888" xml_f="8889" txt_i="5173" txt_f="5174">1</offsets></xref><offsets xml_i="8896" xml_f="8898" txt_i="5174" txt_f="5176">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="8997" xml_f="9015" txt_i="5177" txt_f="5195">Selection criteria</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="9063" xml_f="9086" txt_i="5195" txt_f="5218">BT recommended, do well</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="9134" xml_f="9151" txt_i="5218" txt_f="5235">BT optional, fair</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="9199" xml_f="9225" txt_i="5235" txt_f="5261">BT investigational, poorly</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9295" xml_f="9306" txt_i="5261" txt_f="5272">PSA (ng/ml)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9354" xml_f="9361" txt_i="5273" txt_f="5277">&lt; 10</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9409" xml_f="9414" txt_i="5278" txt_f="5283">10-20</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9462" xml_f="9469" txt_i="5284" txt_f="5288">&gt; 20</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9524" xml_f="9537" txt_i="5289" txt_f="5302">Gleason score</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9585" xml_f="9588" txt_i="5303" txt_f="5306">5-6</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9636" xml_f="9637" txt_i="5307" txt_f="5308">7</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9685" xml_f="9689" txt_i="5309" txt_f="5313">8-10</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9744" xml_f="9749" txt_i="5314" txt_f="5319">Stage</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9797" xml_f="9804" txt_i="5320" txt_f="5327">T1c-T2a</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9852" xml_f="9859" txt_i="5328" txt_f="5335">T2b-T2c</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9907" xml_f="9909" txt_i="5336" txt_f="5338">T3</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9964" xml_f="9968" txt_i="5339" txt_f="5343">IPSS</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10016" xml_f="10019" txt_i="5344" txt_f="5347">0-8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10067" xml_f="10071" txt_i="5348" txt_f="5352">9-19</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10119" xml_f="10126" txt_i="5353" txt_f="5357">&gt; 20</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10181" xml_f="10200" txt_i="5358" txt_f="5377">Prostate volume (cm</offsets><sup><offsets xml_i="10205" xml_f="10206" txt_i="5377" txt_f="5378">3</offsets></sup><offsets xml_i="10212" xml_f="10213" txt_i="5378" txt_f="5379">)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10261" xml_f="10268" txt_i="5380" txt_f="5384">&lt; 40</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10316" xml_f="10321" txt_i="5385" txt_f="5390">40-60</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10369" xml_f="10376" txt_i="5391" txt_f="5395">&gt; 60</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10431" xml_f="10443" txt_i="5396" txt_f="5408">Q max (ml/s)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10491" xml_f="10498" txt_i="5409" txt_f="5413">&gt; 15</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10546" xml_f="10551" txt_i="5414" txt_f="5419">15-10</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10599" xml_f="10606" txt_i="5420" txt_f="5424">&lt; 10</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10661" xml_f="10680" txt_i="5425" txt_f="5444">Residual volume (cm</offsets><sup><offsets xml_i="10685" xml_f="10686" txt_i="5444" txt_f="5445">3</offsets></sup><offsets xml_i="10692" xml_f="10693" txt_i="5445" txt_f="5446">)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10837" xml_f="10845" txt_i="5449" txt_f="5454">&gt; 200</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10900" xml_f="10906" txt_i="5455" txt_f="5461">TURP ±</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="11050" xml_f="11051" txt_i="5464" txt_f="5465">+</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="11101" xml_f="11231" txt_i="5466" txt_f="5596">IPSS – International Prostate Symptom Score, Q – maximum urinary flow rate in ml/s, TURP – transurethral resection of the prostate</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label><offsets xml_i="11318" xml_f="11325" txt_i="5597" txt_f="5604">Table 2</offsets></label><caption><p><offsets xml_i="11345" xml_f="11450" txt_i="5604" txt_f="5709">Indications and contraindications for LDR-BT monotherapy according to ABS and GEC-ESTRO recommendations [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="11486" xml_f="11487" txt_i="5709" txt_f="5710">1</offsets></xref><offsets xml_i="11494" xml_f="11496" txt_i="5710" txt_f="5712">, </offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="11532" xml_f="11533" txt_i="5712" txt_f="5713">4</offsets></xref><offsets xml_i="11540" xml_f="11542" txt_i="5713" txt_f="5715">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="11641" xml_f="11659" txt_i="5716" txt_f="5734">Selection criteria</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="11707" xml_f="11727" txt_i="5734" txt_f="5754">ABS (low risk group)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="11775" xml_f="11784" txt_i="5754" txt_f="5763">GEC-ESTRO</offsets></th></tr></thead><tbody><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="11856" xml_f="11857" txt_i="5763" txt_f="5764">
</offsets><bold><offsets xml_i="11863" xml_f="11874" txt_i="5764" txt_f="5775">Indications</offsets></bold><offsets xml_i="11881" xml_f="11882" txt_i="5775" txt_f="5776">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="11937" xml_f="11948" txt_i="5777" txt_f="5788">PSA (ng/ml)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="11996" xml_f="12003" txt_i="5789" txt_f="5793">&lt; 10</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12051" xml_f="12058" txt_i="5794" txt_f="5798">&lt; 10</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12113" xml_f="12126" txt_i="5799" txt_f="5812">Gleason score</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12174" xml_f="12177" txt_i="5813" txt_f="5816">2-6</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12225" xml_f="12228" txt_i="5817" txt_f="5820">5-6</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12283" xml_f="12288" txt_i="5821" txt_f="5826">Stage</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12336" xml_f="12342" txt_i="5827" txt_f="5833">T1-T2a</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12390" xml_f="12397" txt_i="5834" txt_f="5841">T1c-T2a</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12452" xml_f="12460" txt_i="5842" txt_f="5850">AUA/IPSS</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12508" xml_f="12517" txt_i="5851" txt_f="5860">Low (1-7)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12565" xml_f="12568" txt_i="5861" txt_f="5864">0-8</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12623" xml_f="12642" txt_i="5865" txt_f="5884">Prostate volume (cm</offsets><sup><offsets xml_i="12647" xml_f="12648" txt_i="5884" txt_f="5885">3</offsets></sup><offsets xml_i="12654" xml_f="12655" txt_i="5885" txt_f="5886">)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12703" xml_f="12710" txt_i="5887" txt_f="5891">&lt; 60</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12758" xml_f="12765" txt_i="5892" txt_f="5896">&lt; 50</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12820" xml_f="12832" txt_i="5897" txt_f="5909">Q max (ml/s)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12880" xml_f="12881" txt_i="5910" txt_f="5911">–</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="12929" xml_f="12936" txt_i="5912" txt_f="5916">&gt; 15</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12991" xml_f="13010" txt_i="5917" txt_f="5936">Residual volume (cm</offsets><sup><offsets xml_i="13015" xml_f="13016" txt_i="5936" txt_f="5937">3</offsets></sup><offsets xml_i="13022" xml_f="13023" txt_i="5937" txt_f="5938">)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13071" xml_f="13072" txt_i="5939" txt_f="5940">–</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13120" xml_f="13128" txt_i="5941" txt_f="5946">&lt; 200</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13183" xml_f="13189" txt_i="5947" txt_f="5953">TURP ±</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13237" xml_f="13238" txt_i="5954" txt_f="5955">–</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13286" xml_f="13287" txt_i="5956" txt_f="5957">–</offsets></td></tr><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="13344" xml_f="13345" txt_i="5958" txt_f="5959">
</offsets><bold><offsets xml_i="13351" xml_f="13368" txt_i="5959" txt_f="5976">Contraindications</offsets></bold><offsets xml_i="13375" xml_f="13376" txt_i="5976" txt_f="5977">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13431" xml_f="13446" txt_i="5978" txt_f="5993">Life expectancy</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13494" xml_f="13506" txt_i="5994" txt_f="6003">&lt; 5 years</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13554" xml_f="13566" txt_i="6004" txt_f="6013">&lt; 5 years</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13621" xml_f="13625" txt_i="6014" txt_f="6018">TURP</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13673" xml_f="13703" txt_i="6019" txt_f="6049">Large and poorly healed defect</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13751" xml_f="13769" txt_i="6050" txt_f="6068">Exclusion criteria</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13824" xml_f="13842" txt_i="6069" txt_f="6087">Distant metastases</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13890" xml_f="13891" txt_i="6088" txt_f="6089">+</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13939" xml_f="13940" txt_i="6090" txt_f="6091">+</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13995" xml_f="14009" txt_i="6092" txt_f="6106">Gland size (cm</offsets><sup><offsets xml_i="14014" xml_f="14015" txt_i="6106" txt_f="6107">3</offsets></sup><offsets xml_i="14021" xml_f="14022" txt_i="6107" txt_f="6108">)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14070" xml_f="14077" txt_i="6109" txt_f="6113">&gt; 60</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14125" xml_f="14132" txt_i="6114" txt_f="6118">&gt; 50</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14187" xml_f="14190" txt_i="6119" txt_f="6122">BPH</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14238" xml_f="14267" txt_i="6123" txt_f="6152">– (relative contraindication)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14315" xml_f="14316" txt_i="6153" txt_f="6154">–</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14371" xml_f="14394" txt_i="6155" txt_f="6178">Pubic arch interference</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14442" xml_f="14471" txt_i="6179" txt_f="6208">+ (relative contraindication)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14519" xml_f="14548" txt_i="6209" txt_f="6238">+ (relative contraindication)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14603" xml_f="14620" txt_i="6239" txt_f="6256">Bleeding disorder</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14668" xml_f="14669" txt_i="6257" txt_f="6258">–</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14717" xml_f="14718" txt_i="6259" txt_f="6260">+</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14773" xml_f="14798" txt_i="6261" txt_f="6286">Positive seminal vesicles</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14846" xml_f="14875" txt_i="6287" txt_f="6316">– (relative contraindication)</offsets></td><td align="center" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="14973" xml_f="15138" txt_i="6318" txt_f="6483">IPSS – International Prostate Symptom Score, Q – maximum urinary flow rate in ml/s, TURP – transurethral resection of the prostate, BPH – benign prostate hypertrophy</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="S20003"><title><offsets xml_i="15208" xml_f="15236" txt_i="6485" txt_f="6513">High-dose-rate brachytherapy</offsets></title><p><offsets xml_i="15247" xml_f="15379" txt_i="6514" txt_f="6646">High-dose-rate brachytherapy is a temporary type of brachytherapy where the high-dose rate radioactive source (usually iridium 192 [</offsets><sup><offsets xml_i="15384" xml_f="15387" txt_i="6646" txt_f="6649">192</offsets></sup><offsets xml_i="15393" xml_f="15411" txt_i="6649" txt_f="6667">Ir] or cobalt 60 [</offsets><sup><offsets xml_i="15416" xml_f="15418" txt_i="6667" txt_f="6669">60</offsets></sup><offsets xml_i="15424" xml_f="15580" txt_i="6669" txt_f="6825">Co]) is placed in the gland during the applicator implantation procedure. In Europe, since at least 30 years, HDR-BT has been developed parallel to LDR-BT [</offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="15616" xml_f="15618" txt_i="6825" txt_f="6827">15</offsets></xref><offsets xml_i="15625" xml_f="15626" txt_i="6827" txt_f="6828">–</offsets><xref ref-type="bibr" rid="CIT0020"><offsets xml_i="15662" xml_f="15664" txt_i="6828" txt_f="6830">20</offsets></xref><offsets xml_i="15671" xml_f="16248" txt_i="6830" txt_f="7407">], and in the last years with growing interest in the USA. High-dose-rate equipment is commonly available and the radioactive source used for treatment is the same as in the case of other neoplasms. The dwell-time position of the source in the applicators may be freely programmed during the procedure. The dwell time may be adapted to the requirements of treatment. In the course of treatment and real-time planning, the possibility of imprecise indication of the applicators position in relation to the treated gland is minimal, which ensures high precision of the treatment.</offsets></p><p><offsets xml_i="16255" xml_f="16388" txt_i="7408" txt_f="7541">Initially HDR-BT was introduced as a high-dose-rate supplement for EBRT, and proved to be an effective and safe method of treatment [</offsets><xref ref-type="bibr" rid="CIT0021"><offsets xml_i="16424" xml_f="16426" txt_i="7541" txt_f="7543">21</offsets></xref><offsets xml_i="16433" xml_f="16434" txt_i="7543" txt_f="7544">–</offsets><xref ref-type="bibr" rid="CIT0025"><offsets xml_i="16470" xml_f="16472" txt_i="7544" txt_f="7546">25</offsets></xref><offsets xml_i="16479" xml_f="16619" txt_i="7546" txt_f="7686">]. Treatment of patients from the low and intermediate risk groups with HDR-BT monotherapy was initiated at the end of the previous decade [</offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="16655" xml_f="16657" txt_i="7686" txt_f="7688">15</offsets></xref><offsets xml_i="16664" xml_f="16666" txt_i="7688" txt_f="7690">, </offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="16702" xml_f="16704" txt_i="7690" txt_f="7692">26</offsets></xref><offsets xml_i="16711" xml_f="16712" txt_i="7692" txt_f="7693">–</offsets><xref ref-type="bibr" rid="CIT0032"><offsets xml_i="16748" xml_f="16750" txt_i="7693" txt_f="7695">32</offsets></xref><offsets xml_i="16757" xml_f="16759" txt_i="7695" txt_f="7697">].</offsets></p><p><offsets xml_i="16766" xml_f="17009" txt_i="7698" txt_f="7941">The presence of both brachytherapy techniques in many countries is interesting to compare. The aim of this publication is to describe indications, similarities and differences of both brachytherapy techniques used in prostate cancer treatment.</offsets></p></sec></sec><sec id="S0004"><title><offsets xml_i="17048" xml_f="17077" txt_i="7944" txt_f="7973">Indications for brachytherapy</offsets></title><p><offsets xml_i="17088" xml_f="17513" txt_i="7974" txt_f="8399">The American Brachytherapy Society (ABS) and the Groupe Europeen de Curietherapie–European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) has formed recommendations on consensus panel through clinical experience of experts and their analysis of published data. According to their publications, the appropriate candidates for LDR and HDR monotherapy are patients with a high probability of organ-confined disease (</offsets><xref ref-type="table" rid="T0001"><offsets xml_i="17548" xml_f="17556" txt_i="8399" txt_f="8407">Tables 1</offsets></xref><offsets xml_i="17563" xml_f="17568" txt_i="8407" txt_f="8412"> and </offsets><xref ref-type="table" rid="T0003"><offsets xml_i="17603" xml_f="17604" txt_i="8412" txt_f="8413">3</offsets></xref><offsets xml_i="17611" xml_f="18302" txt_i="8413" txt_f="9104">). It is a general agreement not to apply LDR-BT or HDR-BT alone on patients with significant risk of extra prostatic extension. Most of physicians defines this group by the presence of at least two main risk factors such as PSA level greater than 20 ng/ml, stage higher than T2b and/or Gleason score greater than 7. It is to note that inclusions for HDR-BT include selected T4 cases (in combined therapy). In general intermediate risk group (at least one of the risk factors mentioned above) is not an absolute contraindication of a single BT modality treatment. Good results published by several authors change the physicians preferences to monotherapy combined with androgen deprivation [</offsets><xref ref-type="bibr" rid="CIT0034"><offsets xml_i="18338" xml_f="18340" txt_i="9104" txt_f="9106">34</offsets></xref><offsets xml_i="18347" xml_f="18443" txt_i="9106" txt_f="9202">]. However, to confirm these prospective observations, comprehensive studies are inevitable. In </offsets><xref ref-type="table" rid="T0004"><offsets xml_i="18478" xml_f="18485" txt_i="9202" txt_f="9209">Table 4</offsets></xref><offsets xml_i="18492" xml_f="18574" txt_i="9209" txt_f="9291"> inclusions for LDR-BT and HDR-BT monotherapy and combined therapy are presented.
</offsets></p><table-wrap id="T0003" position="float"><label><offsets xml_i="18625" xml_f="18632" txt_i="9292" txt_f="9299">Table 3</offsets></label><caption><p><offsets xml_i="18652" xml_f="18733" txt_i="9299" txt_f="9380">General inclusion criteria for HDR-BT and LDR-BT according to ABS and GEC-ESTRO [</offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="18769" xml_f="18771" txt_i="9380" txt_f="9382">15</offsets></xref><offsets xml_i="18778" xml_f="18780" txt_i="9382" txt_f="9384">, </offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="18816" xml_f="18818" txt_i="9384" txt_f="9386">26</offsets></xref><offsets xml_i="18825" xml_f="18827" txt_i="9386" txt_f="9388">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="18863" xml_f="18865" txt_i="9388" txt_f="9390">33</offsets></xref><offsets xml_i="18872" xml_f="18874" txt_i="9390" txt_f="9392">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="18973" xml_f="19011" txt_i="9393" txt_f="9431">ABS Prostate High-Dose Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="19057" xml_f="19094" txt_i="9431" txt_f="9468">ABS Prostate Low-Dose Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="19140" xml_f="19164" txt_i="9468" txt_f="9492">GEC-ESTRO High-Dose-Rate</offsets></th></tr></thead><tbody><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="19236" xml_f="19237" txt_i="9492" txt_f="9493">
</offsets><bold><offsets xml_i="19243" xml_f="19257" txt_i="9493" txt_f="9507">Clinical stage</offsets></bold><offsets xml_i="19264" xml_f="19265" txt_i="9507" txt_f="9508">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19320" xml_f="19342" txt_i="9509" txt_f="9531">T1-T3b and selected T4</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19388" xml_f="19411" txt_i="9532" txt_f="9555">T1b-T2c and selected T3</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19457" xml_f="19464" txt_i="9556" txt_f="9563">T1b–T3b</offsets></td></tr><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="19521" xml_f="19522" txt_i="9564" txt_f="9565">
</offsets><bold><offsets xml_i="19528" xml_f="19541" txt_i="9565" txt_f="9578">Gleason score</offsets></bold><offsets xml_i="19548" xml_f="19549" txt_i="9578" txt_f="9579">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19604" xml_f="19608" txt_i="9580" txt_f="9584">2-10</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19654" xml_f="19658" txt_i="9585" txt_f="9589">2-10</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19704" xml_f="19721" txt_i="9590" txt_f="9607">Any Gleason score</offsets></td></tr><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="19778" xml_f="19779" txt_i="9608" txt_f="9609">
</offsets><bold><offsets xml_i="19785" xml_f="19788" txt_i="9609" txt_f="9612">PSA</offsets></bold><offsets xml_i="19795" xml_f="19796" txt_i="9612" txt_f="9613">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19851" xml_f="19952" txt_i="9614" txt_f="9715">No upper limit, but in almost all cases, patient does not have documented distant metastasis (TxN0M0)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19998" xml_f="20043" txt_i="9716" txt_f="9761">In almost all cases, a PSA ≤ 50 ng/ml, N0, M0</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20089" xml_f="20124" txt_i="9762" txt_f="9797">Any iPSA without distant metastases</offsets></td></tr></tbody></table></table-wrap><table-wrap id="T0004" position="float"><label><offsets xml_i="20210" xml_f="20217" txt_i="9798" txt_f="9805">Table 4</offsets></label><caption><p><offsets xml_i="20237" xml_f="20318" txt_i="9805" txt_f="9886">Patient selection criteria for HDR-BT and LDR-BT according to ABS and GEC-ESTRO [</offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="20354" xml_f="20355" txt_i="9886" txt_f="9887">4</offsets></xref><offsets xml_i="20362" xml_f="20364" txt_i="9887" txt_f="9889">, </offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="20400" xml_f="20402" txt_i="9889" txt_f="9891">15</offsets></xref><offsets xml_i="20409" xml_f="20411" txt_i="9891" txt_f="9893">, </offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="20447" xml_f="20449" txt_i="9893" txt_f="9895">26</offsets></xref><offsets xml_i="20456" xml_f="20458" txt_i="9895" txt_f="9897">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="20494" xml_f="20496" txt_i="9897" txt_f="9899">33</offsets></xref><offsets xml_i="20503" xml_f="20505" txt_i="9899" txt_f="9901">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="20604" xml_f="20642" txt_i="9902" txt_f="9940">ABS Prostate High-Dose Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="20688" xml_f="20725" txt_i="9940" txt_f="9977">ABS Prostate Low-Dose Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="20771" xml_f="20810" txt_i="9977" txt_f="10016">GEC-ESTRO High-Dose-Rate, Low-Dose-Rate</offsets></th></tr></thead><tbody><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="20882" xml_f="20883" txt_i="10016" txt_f="10017">
</offsets><bold><offsets xml_i="20889" xml_f="20900" txt_i="10017" txt_f="10028">Monotherapy</offsets></bold><offsets xml_i="20907" xml_f="20908" txt_i="10028" txt_f="10029">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20963" xml_f="21021" txt_i="10030" txt_f="10088">Clinical T1b-T2b and Gleason score ≤ 7 and PSA ≤ 10 ng/ml.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21067" xml_f="21132" txt_i="10089" txt_f="10154">Clinical stage T1b-T2b and Gleason score ≤ 6 and PSA ≤ 10 ng/ml. </offsets><break></break><offsets xml_i="21147" xml_f="21175" txt_i="10154" txt_f="10182">Select higher risk patients.</offsets><break></break><offsets xml_i="21190" xml_f="21235" txt_i="10182" txt_f="10227">Salvage of select radiation therapy failures.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21281" xml_f="21324" txt_i="10228" txt_f="10268">Clinical stage T1b-T2a. iPSA &lt; 10 ng/ml.</offsets><break></break><offsets xml_i="21339" xml_f="21360" txt_i="10268" txt_f="10289">Gleason score max. 6.</offsets></td></tr><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="21417" xml_f="21418" txt_i="10290" txt_f="10291">
</offsets><bold><offsets xml_i="21424" xml_f="21429" txt_i="10291" txt_f="10296">Boost</offsets></bold><offsets xml_i="21436" xml_f="21437" txt_i="10296" txt_f="10297">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="21492" xml_f="21585" txt_i="10298" txt_f="10388">Patients with high risk features such as T3-T4, Gleason score 7-10, and/or PSA &gt; 10 ng/ml.</offsets><break></break><offsets xml_i="21600" xml_f="21754" txt_i="10388" txt_f="10542">Selected patients with “bulky” T1-2b tumor (inadequate information exists to clearly define bulky tumor based on DRE, TRUS, percentage positive biopsies).</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21800" xml_f="21871" txt_i="10543" txt_f="10611">≥ Clinical stage T2c and/or Gleason score ≥ 7 and/or PSA &gt; 10 ng/ml.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21917" xml_f="21932" txt_i="10612" txt_f="10627">Stages T1b-T3b.</offsets><break></break><offsets xml_i="21947" xml_f="21965" txt_i="10627" txt_f="10645">Any Gleason score.</offsets><break></break><offsets xml_i="21980" xml_f="22016" txt_i="10645" txt_f="10681">Any iPSA without distant metastases.</offsets></td></tr><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="22073" xml_f="22074" txt_i="10682" txt_f="10683">
</offsets><bold><offsets xml_i="22080" xml_f="22107" txt_i="10683" txt_f="10710">Special clinical situations</offsets></bold><offsets xml_i="22114" xml_f="22115" txt_i="10710" txt_f="10711">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22216" xml_f="22379" txt_i="10713" txt_f="10876">Inadequate information exists to recommend supplemental EBRT based on perineural invasion, percent positive biopsies and/or MRI-detected extracapsular penetration.</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="22475" xml_f="22612" txt_i="10878" txt_f="11015">DRE – digital rectal examination, TRUS – transrectal ultrasound, EBRT – external beam radiation therapy, MRI – magnetic resonance imaging</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="S0005"><title><offsets xml_i="22681" xml_f="22698" txt_i="11017" txt_f="11034">Contraindications</offsets></title><p><offsets xml_i="22709" xml_f="22868" txt_i="11035" txt_f="11194">ABS and GEC-ESTRO recommends LDR-BT and HDR-BT in patients with at least 5 years of expected survival rate, what seems to be rather relative contraindication [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="22904" xml_f="22905" txt_i="11194" txt_f="11195">1</offsets></xref><offsets xml_i="22912" xml_f="22914" txt_i="11195" txt_f="11197">, </offsets><xref ref-type="bibr" rid="CIT0014"><offsets xml_i="22950" xml_f="22952" txt_i="11197" txt_f="11199">14</offsets></xref><offsets xml_i="22959" xml_f="22961" txt_i="11199" txt_f="11201">, </offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="22997" xml_f="22999" txt_i="11201" txt_f="11203">15</offsets></xref><offsets xml_i="23006" xml_f="23066" txt_i="11203" txt_f="11263">]. It is not included in HDR-BT Task Group recommendations (</offsets><xref ref-type="table" rid="T0005"><offsets xml_i="23101" xml_f="23108" txt_i="11263" txt_f="11270">Table 5</offsets></xref><offsets xml_i="23115" xml_f="23118" txt_i="11270" txt_f="11273">) [</offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="23154" xml_f="23156" txt_i="11273" txt_f="11275">26</offsets></xref><offsets xml_i="23163" xml_f="23165" txt_i="11275" txt_f="11277">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="23201" xml_f="23203" txt_i="11277" txt_f="11279">33</offsets></xref><offsets xml_i="23210" xml_f="23334" txt_i="11279" txt_f="11403">]. According to their publications, neoadjuvant androgen deprivation can decrease volume of the gland before brachytherapy [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="23370" xml_f="23371" txt_i="11403" txt_f="11404">1</offsets></xref><offsets xml_i="23378" xml_f="23639" txt_i="11404" txt_f="11665">]. No nodal involvement and absence of distant metastases are basic points in definition of organ-confined prostate cancer. Patients with disseminated disease can not be cured by radical treatment with both techniques, which is not clearly mentioned in Hsu I-C </offsets><italic><offsets xml_i="23647" xml_f="23652" txt_i="11665" txt_f="11670">et al</offsets></italic><offsets xml_i="23661" xml_f="23680" txt_i="11670" txt_f="11689">. recommendations [</offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="23716" xml_f="23718" txt_i="11689" txt_f="11691">26</offsets></xref><offsets xml_i="23725" xml_f="24046" txt_i="11691" txt_f="12012">]. Transurethral resection of the prostate (TURP) is another relative contraindication for brachytherapy, and is associated with higher rate (∼50%) of urinary incontinence after procedure. Nevertheless, several publications did not confirmed these data and proved that risk of this kind of complication is less than 10% [</offsets><xref ref-type="bibr" rid="CIT0035"><offsets xml_i="24082" xml_f="24084" txt_i="12012" txt_f="12014">35</offsets></xref><offsets xml_i="24091" xml_f="24811" txt_i="12014" txt_f="12734">]. Pubic arch interference as a result of large prostate may preclude adequate placement of seeds, which is the reason why volume of prostate higher than 60 ml seems to be relative contraindication. Potential solution of this difficulty in most cases is hormonal ablation for 3 months before the procedure. Neoadjuvant hormone deprivation can also reduce significant preoperative obstructive symptom, which is again a possible serious contraindication for brachytherapy, which decreases the probability of postoperative acute urinary retention. Several authors reported that downsizing of the prostate gland by 25-40% enables BT procedure, and reduces the risk of obstructive complication in patients with large glands [</offsets><xref ref-type="bibr" rid="CIT0036"><offsets xml_i="24847" xml_f="24849" txt_i="12734" txt_f="12736">36</offsets></xref><offsets xml_i="24856" xml_f="24984" txt_i="12736" txt_f="12864">]. It is worth to note that contraindications are defined in different mode in LDR-BT Task Group and GEC-ESTRO recommendations (</offsets><xref ref-type="table" rid="T0005"><offsets xml_i="25019" xml_f="25026" txt_i="12864" txt_f="12871">Table 5</offsets></xref><offsets xml_i="25033" xml_f="25036" txt_i="12871" txt_f="12874">).
</offsets></p><table-wrap id="T0005" position="float"><label><offsets xml_i="25087" xml_f="25094" txt_i="12875" txt_f="12882">Table 5</offsets></label><caption><p><offsets xml_i="25114" xml_f="25187" txt_i="12882" txt_f="12955">Exclusion criteria for HDR-BT and LDR-BT according to ABS and GEC-ESTRO [</offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="25223" xml_f="25224" txt_i="12955" txt_f="12956">4</offsets></xref><offsets xml_i="25231" xml_f="25233" txt_i="12956" txt_f="12958">, </offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="25269" xml_f="25271" txt_i="12958" txt_f="12960">15</offsets></xref><offsets xml_i="25278" xml_f="25280" txt_i="12960" txt_f="12962">, </offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="25316" xml_f="25318" txt_i="12962" txt_f="12964">26</offsets></xref><offsets xml_i="25325" xml_f="25327" txt_i="12964" txt_f="12966">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="25363" xml_f="25365" txt_i="12966" txt_f="12968">33</offsets></xref><offsets xml_i="25372" xml_f="25374" txt_i="12968" txt_f="12970">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="25473" xml_f="25511" txt_i="12971" txt_f="13009">ABS Prostate High-Dose-Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="25557" xml_f="25594" txt_i="13009" txt_f="13046">ABS Prostate Low-Dose-Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="25640" xml_f="25679" txt_i="13046" txt_f="13085">GEC-ESTRO High-Dose-Rate, Low-Dose-Rate</offsets></th></tr></thead><tbody><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="25751" xml_f="25752" txt_i="13085" txt_f="13086">
</offsets><bold><offsets xml_i="25758" xml_f="25784" txt_i="13086" txt_f="13112">Relative contraindications</offsets></bold><offsets xml_i="25791" xml_f="25792" txt_i="13112" txt_f="13113">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25847" xml_f="25884" txt_i="13114" txt_f="13151">Severe urinary obstructive symptoms. </offsets><break></break><offsets xml_i="25899" xml_f="25944" txt_i="13151" txt_f="13196">Extensive TURP defect or TURP within 6 month.</offsets><break></break><offsets xml_i="25959" xml_f="25985" txt_i="13196" txt_f="13222">Collagen vascular disease.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26031" xml_f="26084" txt_i="13223" txt_f="13276">Severe urinary irritative/obstructive symptomatology.</offsets><break></break><offsets xml_i="26099" xml_f="26121" txt_i="13276" txt_f="13298">Extensive TURP defect.</offsets><break></break><offsets xml_i="26136" xml_f="26172" txt_i="13298" txt_f="13334">Substantial median lobe hyperplasia.</offsets><break></break><offsets xml_i="26187" xml_f="26281" txt_i="13334" txt_f="13422">Prostate dimensions larger than the grid (i.e., &gt; 60 mm in width and &gt; 50 mm in height).</offsets><break></break><offsets xml_i="26296" xml_f="26327" txt_i="13422" txt_f="13453">Severe pubic arch interference.</offsets><break></break><offsets xml_i="26342" xml_f="26376" txt_i="13453" txt_f="13487">Gross seminal vesicle involvement.</offsets><break></break><offsets xml_i="26391" xml_f="26417" txt_i="13487" txt_f="13513">Prior pelvic radiotherapy.</offsets><break></break><offsets xml_i="26432" xml_f="26459" txt_i="13513" txt_f="13540">Inflammatory bowel disease.</offsets><break></break><offsets xml_i="26474" xml_f="26519" txt_i="13540" txt_f="13585">Pathologic involvement of pelvic lymph nodes.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26565" xml_f="26582" txt_i="13586" txt_f="13600">Volume &gt; 60 cm</offsets><sup><offsets xml_i="26587" xml_f="26588" txt_i="13600" txt_f="13601">3</offsets></sup><offsets xml_i="26594" xml_f="26595" txt_i="13601" txt_f="13602">.</offsets><break></break><offsets xml_i="26610" xml_f="26631" txt_i="13602" txt_f="13623">TURP within 6 months.</offsets><break></break><offsets xml_i="26646" xml_f="26705" txt_i="13623" txt_f="13682">Infiltration of the external sphincter of the bladder neck.</offsets><break></break><offsets xml_i="26720" xml_f="26761" txt_i="13682" txt_f="13723">Significant urinary obstructive symptoms.</offsets><break></break><offsets xml_i="26776" xml_f="26800" txt_i="13723" txt_f="13747">Pubic arch interference.</offsets><break></break><offsets xml_i="26815" xml_f="26858" txt_i="13747" txt_f="13787">Rectum-prostate distance on TRUS &lt; 5 mm.</offsets><break></break><offsets xml_i="26873" xml_f="26920" txt_i="13787" txt_f="13834">Lithotomic position or anesthesia not possible.</offsets></td></tr><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="26977" xml_f="26978" txt_i="13835" txt_f="13836">
</offsets><bold><offsets xml_i="26984" xml_f="27010" txt_i="13836" txt_f="13862">Absolute contraindications</offsets></bold><offsets xml_i="27017" xml_f="27018" txt_i="13862" txt_f="13863">
</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27073" xml_f="27140" txt_i="13864" txt_f="13931">Unable to undergo anesthesia (general, spinal, epidural, or local).</offsets><break></break><offsets xml_i="27155" xml_f="27174" txt_i="13931" txt_f="13950">Unable to lay flat.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27220" xml_f="27239" txt_i="13951" txt_f="13970">Distant metastases.</offsets><break></break><offsets xml_i="27254" xml_f="27283" txt_i="13970" txt_f="13996">Life expectancy &lt; 5 years.</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="27379" xml_f="27425" txt_i="13998" txt_f="14044">TURP – transurethral resection of the prostate</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="S0006"><title><offsets xml_i="27494" xml_f="27517" txt_i="14046" txt_f="14069">Implantation techniques</offsets></title><p><offsets xml_i="27528" xml_f="29371" txt_i="14070" txt_f="15913">Most of both brachytherapy technical steps are similar. Many centers has improved and introduced their own techniques. Preoperative workup before brachytherapy insertion includes mechanical bowel preparation, prophylactic intravenous antibiotics, continued per os for several days afterwards (in some centers). Before the procedure, patients with history of deep vein thrombosis are being given heparin subcutaneously to prevent any complications in connection with these blood condition. Because of significant risk of perineal hemorrhage, the rest of the procedure candidates are to stop receiving anticoagulants, including aspirin, nonsteroidal anti-inflammatory drugs or warfarin. In the operating room, a patient is placed under general or spinal anesthesia in dorsal lithotomic position. After catheterization of contrast or air filled gel that are usually used to visualize the urethra, and to differentiate the bladder from the prostate. First step of the procedure is the necessity to determine the shape and size of the gland by initial trans-rectal ultrasound examination (TRUS) - before needles insertion. It can be done a few days before seeds (needles) insertion (preimplant treatment planning, preplanning) or can be performed on the day of the procedure (intraoperative treatment planning). A biplanar probe at 5, 6, or 7.5 MHz of frequency, gather ultrasound visualization of prostate localization at 0.5 cm intervals, compared with the one after needles insertion. Treatment plan should contain several information such as needle location, number and strength of seeds (or number and position of HDR needles), and shape and volume of the target. To achieve the exact dose inside the prostate it is essential to use nomograms (inadequate amount activity per volume) combined with real-time TRUS and treatment planning system [</offsets><xref ref-type="bibr" rid="CIT0037"><offsets xml_i="29407" xml_f="29409" txt_i="15913" txt_f="15915">37</offsets></xref><offsets xml_i="29416" xml_f="31338" txt_i="15915" txt_f="17837">]. Transrectal ultrasound equipment is combined with special template, and by guiding creates stepping unit. Before proper procedure it is important to measure the distance from bladder base to template. Only then two stabilizing needles are being inserted through the template just posterior to the urethra on either side of the midline. Because of movement of the prostate, during the procedure a pre-plan can be created in order to minimize the risk of positioning errors. The loading pattern indicate coordinates in the computer planning system in connection with the templates stepping unit. That gives the physicians exact points to insert each needle. In this step brachytherapy techniques differ one from other. When the pre-plan is done, 20 cm long needles are inserted, and after consulting two plans (before and after insertion), radioactive seeds (in case of LDR-BT) are placed into the prostate gland. Withdrawing each needle should be done very carefully to avoid source migration inside the gland (LDR-BT). LDR-BT: once the procedure has been completed, the position of seeds must be observed under fluoroscopy and ultrasonography. Usually there is no possibility of removing seeds after insertion and if a “cold spots” are observed, a few extra seeds can be added to cover them. Performing a final CT scan of the prostate and postimplant dosimetry ends up the whole procedure of LDR seeds implantation in prostate cancer treatment. The patient leaves the theatre catheterized, and after removing it, can be discharged home the next day. In LDR-BT there is another advanced technique of seeds implantation worth of mentioning. In stranded seeds technique, the point is to implant radioactive sources embedded in a polymer strand of glycolide, lactide and polydioxanone spaced from 5 mm to over 50 mm apart, and placed in 18-gauge needle. The main advantages of this technique is significant improvement in D</offsets><sub><offsets xml_i="31343" xml_f="31345" txt_i="17837" txt_f="17839">90</offsets></sub><offsets xml_i="31351" xml_f="31444" txt_i="17839" txt_f="17932"> parameter without increasing of toxicity rate and less number of seeds migration incidences.</offsets></p></sec><sec id="S0007"><title><offsets xml_i="31477" xml_f="31482" txt_i="17934" txt_f="17939">Doses</offsets></title><p><offsets xml_i="31493" xml_f="32005" txt_i="17940" txt_f="18452">According to ABS recommendations, patients with organ-confined prostate cancer are to be treated with monotherapy, others – with combined treatment (EBRT in 40-50 Gy dose with BT boost of 110 Gy and 100 Gy depending on which EBRT dose was administered (LDR-BT) or different HDR-BT schemas. The HDR-BT procedure is performed once or repeated several times, depending on the fractionating schema assumed. The ABS proposes three fractionating schemas for HDR-BT monotherapy and four schemas for combined treatment [</offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="32041" xml_f="32043" txt_i="18452" txt_f="18454">26</offsets></xref><offsets xml_i="32050" xml_f="32094" txt_i="18454" txt_f="18498">], however, other schemas are also applied (</offsets><xref ref-type="table" rid="T0006"><offsets xml_i="32129" xml_f="32136" txt_i="18498" txt_f="18505">Table 6</offsets></xref><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="32179" xml_f="32181" txt_i="18505" txt_f="18507">15</offsets></xref><offsets xml_i="32188" xml_f="32190" txt_i="18507" txt_f="18509">, </offsets><xref ref-type="bibr" rid="CIT0016"><offsets xml_i="32226" xml_f="32228" txt_i="18509" txt_f="18511">16</offsets></xref><offsets xml_i="32235" xml_f="32237" txt_i="18511" txt_f="18513">, </offsets><xref ref-type="bibr" rid="CIT0021"><offsets xml_i="32273" xml_f="32275" txt_i="18513" txt_f="18515">21</offsets></xref><offsets xml_i="32282" xml_f="32528" txt_i="18515" txt_f="18761">]. Many different fractionations schema make difficult to compare treatment results. Using radiobiological models we noted also different BEDs (biologically effective doses), comparing to LDR-BT nd HDR-BT – differences are sometimes significant [</offsets><xref ref-type="bibr" rid="CIT0038"><offsets xml_i="32564" xml_f="32566" txt_i="18761" txt_f="18763">38</offsets></xref><offsets xml_i="32573" xml_f="32576" txt_i="18763" txt_f="18766">].
</offsets></p><table-wrap id="T0006" position="float"><label><offsets xml_i="32627" xml_f="32634" txt_i="18767" txt_f="18774">Table 6</offsets></label><caption><p><offsets xml_i="32654" xml_f="32720" txt_i="18774" txt_f="18840">Doses for HDR-BT and LDR-BT according to ABS and ESTRO/EAU/EORTC [</offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="32756" xml_f="32757" txt_i="18840" txt_f="18841">4</offsets></xref><offsets xml_i="32764" xml_f="32766" txt_i="18841" txt_f="18843">, </offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="32802" xml_f="32804" txt_i="18843" txt_f="18845">26</offsets></xref><offsets xml_i="32811" xml_f="32813" txt_i="18845" txt_f="18847">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="32849" xml_f="32851" txt_i="18847" txt_f="18849">33</offsets></xref><offsets xml_i="32858" xml_f="32860" txt_i="18849" txt_f="18851">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="center" rowspan="1" colspan="1"><offsets xml_i="32961" xml_f="32999" txt_i="18852" txt_f="18890">ABS Prostate High-Dose-Rate Task Group</offsets></th><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="33095" xml_f="33166" txt_i="18890" txt_f="18961">ABS Prostate Low-Dose-Rate Task Group and ESTRO/EAU/EORTC Low-Dose-Rate</offsets></th></tr></thead><tbody><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="33238" xml_f="33239" txt_i="18961" txt_f="18962">
</offsets><bold><offsets xml_i="33245" xml_f="33256" txt_i="18962" txt_f="18973">Monotherapy</offsets></bold><offsets xml_i="33263" xml_f="33264" txt_i="18973" txt_f="18974">
</offsets></td></tr><tr><td align="center" rowspan="1" colspan="1"><offsets xml_i="33321" xml_f="33332" txt_i="18975" txt_f="18986">10.5 Gy × 3</offsets><break></break><offsets xml_i="33347" xml_f="33361" txt_i="18986" txt_f="19000">8.5-9.5 Gy × 4</offsets><break></break><offsets xml_i="33376" xml_f="33390" txt_i="19000" txt_f="19014">6.0-7.5 Gy × 6</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33486" xml_f="33487" txt_i="19016" txt_f="19017">
</offsets><sup><offsets xml_i="33492" xml_f="33495" txt_i="19017" txt_f="19020">103</offsets></sup><offsets xml_i="33501" xml_f="33532" txt_i="19020" txt_f="19051">Pd – median 125 Gy (110-120 Gy)</offsets><break></break><offsets xml_i="33547" xml_f="33548" txt_i="19051" txt_f="19052">
</offsets><sup><offsets xml_i="33553" xml_f="33556" txt_i="19052" txt_f="19055">125</offsets></sup><offsets xml_i="33562" xml_f="33592" txt_i="19055" txt_f="19085">I – median 145 Gy (140-160 Gy)</offsets><break></break><offsets xml_i="33607" xml_f="33608" txt_i="19085" txt_f="19086">
</offsets><sup><offsets xml_i="33613" xml_f="33616" txt_i="19086" txt_f="19089">131</offsets></sup><offsets xml_i="33622" xml_f="33633" txt_i="19089" txt_f="19100">Cs – 115 Gy</offsets></td></tr><tr><td colspan="3" align="center" rowspan="1"><offsets xml_i="33690" xml_f="33691" txt_i="19101" txt_f="19102">
</offsets><bold><offsets xml_i="33697" xml_f="33706" txt_i="19102" txt_f="19111">BT + EBRT</offsets></bold><offsets xml_i="33713" xml_f="33714" txt_i="19111" txt_f="19112">
</offsets></td></tr><tr><td align="center" rowspan="1" colspan="1"><offsets xml_i="33771" xml_f="33801" txt_i="19113" txt_f="19143">15 Gy × 1 (with 36-40 Gy EBRT)</offsets><break></break><offsets xml_i="33816" xml_f="33852" txt_i="19143" txt_f="19179">9.5-10.5 Gy × 2 (with 40-50 Gy EBRT)</offsets><break></break><offsets xml_i="33867" xml_f="33902" txt_i="19179" txt_f="19214">5.5-7.5 Gy × 3 (with 40-50 Gy EBRT)</offsets><break></break><offsets xml_i="33917" xml_f="33952" txt_i="19214" txt_f="19249">4.0-6.0 Gy × 4 (with 36-50 Gy EBRT)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="34048" xml_f="34049" txt_i="19251" txt_f="19252">
</offsets><sup><offsets xml_i="34054" xml_f="34057" txt_i="19252" txt_f="19255">103</offsets></sup><offsets xml_i="34063" xml_f="34065" txt_i="19255" txt_f="19257">Pd</offsets><break></break><offsets xml_i="34080" xml_f="34110" txt_i="19257" txt_f="19287">Boost (with 41.4-50.4 Gy EBRT)</offsets><break></break><offsets xml_i="34125" xml_f="34134" txt_i="19287" txt_f="19296">90-100 Gy</offsets><break></break><offsets xml_i="34149" xml_f="34150" txt_i="19296" txt_f="19297">
</offsets><sup><offsets xml_i="34155" xml_f="34158" txt_i="19297" txt_f="19300">125</offsets></sup><offsets xml_i="34164" xml_f="34165" txt_i="19300" txt_f="19301">I</offsets><break></break><offsets xml_i="34180" xml_f="34210" txt_i="19301" txt_f="19331">Boost (with 41.4-50.4 Gy EBRT)</offsets><break></break><offsets xml_i="34225" xml_f="34235" txt_i="19331" txt_f="19341">108-110 Gy</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="34285" xml_f="34343" txt_i="19342" txt_f="19400">BT – brachytherapy, EBRT – external beam radiation therapy</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="S0008"><title><offsets xml_i="34412" xml_f="34430" txt_i="19402" txt_f="19420">Treatment planning</offsets></title><p><offsets xml_i="34441" xml_f="34541" txt_i="19421" txt_f="19521">Describing of planning target volume (PTV) for HDR-BT and LDR-BT was published by both Task Groups [</offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="34577" xml_f="34579" txt_i="19521" txt_f="19523">26</offsets></xref><offsets xml_i="34586" xml_f="34588" txt_i="19523" txt_f="19525">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="34624" xml_f="34626" txt_i="19525" txt_f="19527">33</offsets></xref><offsets xml_i="34633" xml_f="34809" txt_i="19527" txt_f="19703">]. The definition of volumes is based on ICRU Report 58. HDR Task Group recommendations are more specific and differs significantly from the recommendations of LDR Task Group (</offsets><xref ref-type="table" rid="T0007"><offsets xml_i="34844" xml_f="34851" txt_i="19703" txt_f="19710">Table 7</offsets></xref><offsets xml_i="34858" xml_f="35023" txt_i="19710" txt_f="19875">). There is a difference between recommended evaluated postoperative dosimetric parameters for HDR and LDR brachytherapy, according to ABS and GEC-ESTRO/ EAU/EORTC [</offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="35059" xml_f="35060" txt_i="19875" txt_f="19876">4</offsets></xref><offsets xml_i="35067" xml_f="35069" txt_i="19876" txt_f="19878">, </offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="35105" xml_f="35107" txt_i="19878" txt_f="19880">15</offsets></xref><offsets xml_i="35114" xml_f="35116" txt_i="19880" txt_f="19882">, </offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="35152" xml_f="35154" txt_i="19882" txt_f="19884">26</offsets></xref><offsets xml_i="35161" xml_f="35163" txt_i="19884" txt_f="19886">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="35199" xml_f="35201" txt_i="19886" txt_f="19888">33</offsets></xref><offsets xml_i="35208" xml_f="35211" txt_i="19888" txt_f="19891">] (</offsets><xref ref-type="table" rid="T0008"><offsets xml_i="35246" xml_f="35253" txt_i="19891" txt_f="19898">Table 8</offsets></xref><offsets xml_i="35260" xml_f="35263" txt_i="19898" txt_f="19901">).
</offsets></p><table-wrap id="T0007" position="float"><label><offsets xml_i="35314" xml_f="35321" txt_i="19902" txt_f="19909">Table 7</offsets></label><caption><p><offsets xml_i="35341" xml_f="35407" txt_i="19909" txt_f="19975">Describing of planning target volume (PTV) for HDR-BT and LDR-BT [</offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="35443" xml_f="35445" txt_i="19975" txt_f="19977">26</offsets></xref><offsets xml_i="35452" xml_f="35454" txt_i="19977" txt_f="19979">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="35490" xml_f="35492" txt_i="19979" txt_f="19981">33</offsets></xref><offsets xml_i="35499" xml_f="35501" txt_i="19981" txt_f="19983">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="35600" xml_f="35638" txt_i="19984" txt_f="20022">ABS Prostate High-Dose-Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="35684" xml_f="35721" txt_i="20022" txt_f="20059">ABS Prostate Low-Dose-Rate Task Group</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="35791" xml_f="35859" txt_i="20059" txt_f="20127">The definition of volumes will be in accordance with ICRU Report 58:</offsets><break></break><offsets xml_i="35874" xml_f="35941" txt_i="20127" txt_f="20194">- dose and volume specification for reporting interstitial therapy,</offsets><break></break><offsets xml_i="35956" xml_f="36022" txt_i="20194" txt_f="20260">- clinical target volume (CTV) is defined by the physician on the </offsets><break></break><offsets xml_i="36037" xml_f="36061" txt_i="20260" txt_f="20284">treatment planning scan,</offsets><break></break><offsets xml_i="36076" xml_f="36139" txt_i="20284" txt_f="20347">- for T1c-T2b the brachytherapy CTV includes the prostate only,</offsets><break></break><offsets xml_i="36154" xml_f="36241" txt_i="20347" txt_f="20434">- for T3a-T3b the brachytherapy CTV includes the prostate and extra-capsular extension,</offsets><break></break><offsets xml_i="36256" xml_f="36268" txt_i="20434" txt_f="20446">- PTV = CTV.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="36314" xml_f="36335" txt_i="20447" txt_f="20468">Prostate with margin.</offsets><break></break><offsets xml_i="36350" xml_f="36367" txt_i="20468" txt_f="20485">Seminal vesicles.</offsets><break></break><offsets xml_i="36382" xml_f="36454" txt_i="20485" txt_f="20557">Prostate minus non-cancerous regions of the gland (e.g., anterior base).</offsets><break></break><offsets xml_i="36469" xml_f="36518" txt_i="20557" txt_f="20606">Image-guided target volumes such as indium-111 or</offsets><break></break><offsets xml_i="36533" xml_f="36549" txt_i="20606" txt_f="20622">MR spectroscopy.</offsets></td></tr></tbody></table></table-wrap><table-wrap id="T0008" position="float"><label><offsets xml_i="36635" xml_f="36642" txt_i="20623" txt_f="20630">Table 8</offsets></label><caption><p><offsets xml_i="36662" xml_f="36792" txt_i="20630" txt_f="20760">Recommended evaluated postoperative dosimetric parameters for HDR and LDR brachytherapy according to ABS and GEC-ESTRO/EAU/EORTC [</offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="36828" xml_f="36829" txt_i="20760" txt_f="20761">4</offsets></xref><offsets xml_i="36836" xml_f="36838" txt_i="20761" txt_f="20763">, </offsets><xref ref-type="bibr" rid="CIT0015"><offsets xml_i="36874" xml_f="36876" txt_i="20763" txt_f="20765">15</offsets></xref><offsets xml_i="36883" xml_f="36885" txt_i="20765" txt_f="20767">, </offsets><xref ref-type="bibr" rid="CIT0026"><offsets xml_i="36921" xml_f="36923" txt_i="20767" txt_f="20769">26</offsets></xref><offsets xml_i="36930" xml_f="36932" txt_i="20769" txt_f="20771">, </offsets><xref ref-type="bibr" rid="CIT0033"><offsets xml_i="36968" xml_f="36970" txt_i="20771" txt_f="20773">33</offsets></xref><offsets xml_i="36977" xml_f="36979" txt_i="20773" txt_f="20775">]
</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="37078" xml_f="37116" txt_i="20776" txt_f="20814">ABS Prostate High-Dose-Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="37162" xml_f="37199" txt_i="20814" txt_f="20851">ABS Prostate Low-Dose-Rate Task Group</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="37245" xml_f="37273" txt_i="20851" txt_f="20879">GEC-ESTRO/EAU High-Dose-Rate</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="37319" xml_f="37348" txt_i="20879" txt_f="20908">ESTRO/EAU/EORTC Low-Dose-Rate</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="37418" xml_f="37470" txt_i="20908" txt_f="20960">The prescription dose will be given only to the PTV.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37516" xml_f="37517" txt_i="20961" txt_f="20962">V</offsets><sub><offsets xml_i="37522" xml_f="37525" txt_i="20962" txt_f="20965">100</offsets></sub><offsets xml_i="37531" xml_f="37532" txt_i="20965" txt_f="20966">
</offsets><break></break><offsets xml_i="37547" xml_f="37548" txt_i="20966" txt_f="20967">V</offsets><sub><offsets xml_i="37553" xml_f="37556" txt_i="20967" txt_f="20970">150</offsets></sub><offsets xml_i="37562" xml_f="37563" txt_i="20970" txt_f="20971">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37609" xml_f="37659" txt_i="20972" txt_f="21022">Dose rate and dose per fraction of the target dose</offsets><break></break><offsets xml_i="37674" xml_f="37676" txt_i="21022" txt_f="21024">(D</offsets><sub><offsets xml_i="37681" xml_f="37684" txt_i="21024" txt_f="21027">100</offsets></sub><offsets xml_i="37690" xml_f="37693" txt_i="21027" txt_f="21030">, D</offsets><sub><offsets xml_i="37698" xml_f="37700" txt_i="21030" txt_f="21032">90</offsets></sub><offsets xml_i="37706" xml_f="37735" txt_i="21032" txt_f="21061">) for CTV 1, CTV 2 and CTV 3.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="37781" xml_f="37802" txt_i="21062" txt_f="21083">The volume implanted.</offsets><break></break><offsets xml_i="37817" xml_f="37837" txt_i="21083" txt_f="21103">The number of seeds.</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="37892" xml_f="37966" txt_i="21104" txt_f="21178">The goal is to deliver the prescription dose to at least 90% of the PTV (V</offsets><sub><offsets xml_i="37971" xml_f="37974" txt_i="21178" txt_f="21181">100</offsets></sub><offsets xml_i="37980" xml_f="38000" txt_i="21181" txt_f="21198"> prostate &gt; 90%).</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38046" xml_f="38047" txt_i="21199" txt_f="21200">V</offsets><sub><offsets xml_i="38052" xml_f="38055" txt_i="21200" txt_f="21203">200</offsets></sub><offsets xml_i="38061" xml_f="38062" txt_i="21203" txt_f="21204">
</offsets><break></break><offsets xml_i="38077" xml_f="38078" txt_i="21204" txt_f="21205">D</offsets><sub><offsets xml_i="38083" xml_f="38085" txt_i="21205" txt_f="21207">90</offsets></sub><offsets xml_i="38091" xml_f="38092" txt_i="21207" txt_f="21208">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38138" xml_f="38175" txt_i="21209" txt_f="21246">Number and duration of the fractions.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38221" xml_f="38248" txt_i="21247" txt_f="21274">The number of needles used.</offsets><break></break><offsets xml_i="38263" xml_f="38292" txt_i="21274" txt_f="21303">The total activity implanted.</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="38347" xml_f="38451" txt_i="21304" txt_f="21408">The volume of bladder and rectum receiving 75% of the prescription dose should be kept to less than 1 cm</offsets><sup><offsets xml_i="38456" xml_f="38457" txt_i="21408" txt_f="21409">3</offsets></sup><offsets xml_i="38463" xml_f="38466" txt_i="21409" txt_f="21412"> (V</offsets><sub><offsets xml_i="38471" xml_f="38473" txt_i="21412" txt_f="21414">75</offsets></sub><offsets xml_i="38479" xml_f="38492" txt_i="21414" txt_f="21427"> rectum and V</offsets><sub><offsets xml_i="38497" xml_f="38499" txt_i="21427" txt_f="21429">75</offsets></sub><offsets xml_i="38505" xml_f="38523" txt_i="21429" txt_f="21444"> bladder &lt; 1 cm</offsets><sup><offsets xml_i="38528" xml_f="38529" txt_i="21444" txt_f="21445">3</offsets></sup><offsets xml_i="38535" xml_f="38537" txt_i="21445" txt_f="21447">).</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38583" xml_f="38618" txt_i="21448" txt_f="21483">Urethral doses – should include: UV</offsets><sub><offsets xml_i="38623" xml_f="38626" txt_i="21483" txt_f="21486">125</offsets></sub><offsets xml_i="38632" xml_f="38636" txt_i="21486" txt_f="21490">, UV</offsets><sub><offsets xml_i="38641" xml_f="38644" txt_i="21490" txt_f="21493">150</offsets></sub><offsets xml_i="38650" xml_f="38654" txt_i="21493" txt_f="21497">, UD</offsets><sub><offsets xml_i="38659" xml_f="38661" txt_i="21497" txt_f="21499">50</offsets></sub><offsets xml_i="38667" xml_f="38668" txt_i="21499" txt_f="21500">,</offsets><break></break><offsets xml_i="38683" xml_f="38685" txt_i="21500" txt_f="21502">UD</offsets><sub><offsets xml_i="38690" xml_f="38692" txt_i="21502" txt_f="21504">30</offsets></sub><offsets xml_i="38698" xml_f="38702" txt_i="21504" txt_f="21508">, UD</offsets><sub><offsets xml_i="38707" xml_f="38708" txt_i="21508" txt_f="21509">5</offsets></sub><offsets xml_i="38714" xml_f="38715" txt_i="21509" txt_f="21510">
</offsets><break></break><offsets xml_i="38730" xml_f="38762" txt_i="21510" txt_f="21542">and/or maximum and minimum dose.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38808" xml_f="38861" txt_i="21543" txt_f="21596">Time interval between fractions and the overall time.</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="38907" xml_f="38927" txt_i="21597" txt_f="21617">The prescribed dose.</offsets><break></break><offsets xml_i="38942" xml_f="38947" txt_i="21617" txt_f="21622">The D</offsets><sub><offsets xml_i="38952" xml_f="38954" txt_i="21622" txt_f="21624">90</offsets></sub><offsets xml_i="38960" xml_f="39055" txt_i="21624" txt_f="21719">, that is the dose that covers 90% of the prostate volume as defined from post implant imaging.</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="39110" xml_f="39204" txt_i="21720" txt_f="21814">The volume of urethra receiving 125% of the prescription dose should be kept to less than 1 cm</offsets><sup><offsets xml_i="39209" xml_f="39210" txt_i="21814" txt_f="21815">3</offsets></sup><offsets xml_i="39216" xml_f="39219" txt_i="21815" txt_f="21818"> (V</offsets><sub><offsets xml_i="39224" xml_f="39227" txt_i="21818" txt_f="21821">125</offsets></sub><offsets xml_i="39233" xml_f="39251" txt_i="21821" txt_f="21836"> urethra &lt; 1 cm</offsets><sup><offsets xml_i="39256" xml_f="39257" txt_i="21836" txt_f="21837">3</offsets></sup><offsets xml_i="39263" xml_f="39265" txt_i="21837" txt_f="21839">).</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="39311" xml_f="39392" txt_i="21840" txt_f="21921">Rectal doses – cubic centimeters of rectum which received ≥ prescription dose (RV</offsets><sub><offsets xml_i="39397" xml_f="39400" txt_i="21921" txt_f="21924">100</offsets></sub><offsets xml_i="39406" xml_f="39408" txt_i="21924" txt_f="21926">).</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="39500" xml_f="39505" txt_i="21928" txt_f="21933">The V</offsets><sub><offsets xml_i="39510" xml_f="39513" txt_i="21933" txt_f="21936">100</offsets></sub><offsets xml_i="39519" xml_f="39605" txt_i="21936" txt_f="22022">, that is the percentage of the prostate volume that has received the prescribed dose.</offsets><break></break><offsets xml_i="39620" xml_f="39621" txt_i="22022" txt_f="22023">V</offsets><sub><offsets xml_i="39626" xml_f="39629" txt_i="22023" txt_f="22026">150</offsets></sub><offsets xml_i="39635" xml_f="39700" txt_i="22026" txt_f="22091">, the volume that has received 50% more than the prescribed dose.</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="39750" xml_f="40109" txt_i="22092" txt_f="22451">GEC-ESTRO – The Groupe Europeen de Curietherapie – European Society for Therapeutic Radiology and Oncology, EAU – European Association of Urology, EORTC – European Organization for Research and Treatment of Cancer, PTV – Planning Target Volume, CTV – Clinical Target Volume, V – volume, D – doses, UV – urethral volume, UD – urethral doses, RV – rectal volume</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="S0009"><title><offsets xml_i="40178" xml_f="40200" txt_i="22453" txt_f="22475">Dosimetry after LDR-BT</offsets></title><p><offsets xml_i="40211" xml_f="40396" txt_i="22476" txt_f="22661">Apart from dosimetric planning of the implant before or during seed insertion, ABS and GEC-ESTRO recommend postimplant dosimetry in all patients after LDR-BT for the best optimal care [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="40432" xml_f="40433" txt_i="22661" txt_f="22662">1</offsets></xref><offsets xml_i="40440" xml_f="40442" txt_i="22662" txt_f="22664">, </offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="40478" xml_f="40479" txt_i="22664" txt_f="22665">4</offsets></xref><offsets xml_i="40486" xml_f="40814" txt_i="22665" txt_f="22993">]. According to availability, cost and exact way to visualize a prostate with implanted seeds, CT-based dosimetry is in the world-wide use nowadays. CT scanning has to be determined by each center at a consistent postoperative intervals to check the evaluation of implanted seeds position and this intervals should be reported [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="40850" xml_f="40851" txt_i="22993" txt_f="22994">1</offsets></xref><offsets xml_i="40858" xml_f="40860" txt_i="22994" txt_f="22996">, </offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="40896" xml_f="40897" txt_i="22996" txt_f="22997">4</offsets></xref><offsets xml_i="40904" xml_f="40906" txt_i="22997" txt_f="22999">, </offsets><xref ref-type="bibr" rid="CIT0007"><offsets xml_i="40942" xml_f="40943" txt_i="22999" txt_f="23000">7</offsets></xref><offsets xml_i="40950" xml_f="41261" txt_i="23000" txt_f="23311">]. On every digital examination, physicians with physicist should obtain isodoses overlapping the gland at 50%, 80%, 90%, 100%, 150% and 200% of the prescribed dose, and compared with dose-volume-histograms (DVH) on previous CT scans. Nevertheless, ABS recommends for all centers to perform DVH and report the D</offsets><sub><offsets xml_i="41266" xml_f="41268" txt_i="23311" txt_f="23313">90</offsets></sub><offsets xml_i="41274" xml_f="41334" txt_i="23313" txt_f="23373"> value (dose received by 90% of the target volume) and the V</offsets><sub><offsets xml_i="41339" xml_f="41342" txt_i="23373" txt_f="23376">100</offsets></sub><offsets xml_i="41348" xml_f="41765" txt_i="23376" txt_f="23793"> (volume received 100% of the prescribed dose). To prevent any serious complication of organs at risk (OaR), the rectal and the urethral doses should be reported and correlated with patient ailments during the interview. In addition to the treatment, post implant radiographs can be performed to verify the seeds location and their number. The dose is usually prescribed at the periphery of the target volume and for </offsets><sup><offsets xml_i="41770" xml_f="41773" txt_i="23793" txt_f="23796">125</offsets></sup><offsets xml_i="41779" xml_f="41782" txt_i="23796" txt_f="23799">I, </offsets><sup><offsets xml_i="41787" xml_f="41790" txt_i="23799" txt_f="23802">103</offsets></sup><offsets xml_i="41796" xml_f="42008" txt_i="23802" txt_f="24014">Pd - it equals to 145, 125 Gy, respectively. The prescribed dose in the centre of radiated volume should not be higher than 150%, what can be achieve by decreasing the number of seeds from potential “hot-spots” [</offsets><xref ref-type="bibr" rid="CIT0003"><offsets xml_i="42044" xml_f="42045" txt_i="24014" txt_f="24015">3</offsets></xref><offsets xml_i="42052" xml_f="42548" txt_i="24015" txt_f="24511">]. Oedema of the gland after implantation procedure is the last point worth of mention in this paragraph. Higher volume of prostate causes worse value of therapeutic dose cover. The use of treatment margin value (TM) in treatment planning should help to cover exact volume of the gland. Anyway, the role of treatment margin around the prostate is to cure possible microscopic disease spread outside the capsule. TM in most cases should be equal not less than 3-5 mm as seen in many publications [</offsets><xref ref-type="bibr" rid="CIT0039"><offsets xml_i="42584" xml_f="42586" txt_i="24511" txt_f="24513">39</offsets></xref><offsets xml_i="42593" xml_f="42601" txt_i="24513" txt_f="24521">]. The V</offsets><sub><offsets xml_i="42606" xml_f="42609" txt_i="24521" txt_f="24524">100</offsets></sub><offsets xml_i="42615" xml_f="42944" txt_i="24524" txt_f="24850"> indicator is used for assessment of the HDR-BT treatment plan for prostatic carcinoma – it provides a percentage value of the treated volume covered by the isodose of the fractionated dose. The American Brachytherapy Society recommends that the fractionated dose should cover &gt; 90% of the planning target volume (PTV), i.e. V</offsets><sub><offsets xml_i="42949" xml_f="42952" txt_i="24850" txt_f="24853">100</offsets></sub><offsets xml_i="42958" xml_f="43080" txt_i="24853" txt_f="24972"> &gt; 90%. In the urinary bladder and rectum, the volume which receives 75% of the reference dose should be less than 1 cm</offsets><sup><offsets xml_i="43085" xml_f="43086" txt_i="24972" txt_f="24973">3</offsets></sup><offsets xml_i="43092" xml_f="43095" txt_i="24973" txt_f="24976"> (V</offsets><sub><offsets xml_i="43100" xml_f="43102" txt_i="24976" txt_f="24978">75</offsets></sub><offsets xml_i="43108" xml_f="43128" txt_i="24978" txt_f="24998"> of the rectum and V</offsets><sub><offsets xml_i="43133" xml_f="43135" txt_i="24998" txt_f="25000">75</offsets></sub><offsets xml_i="43141" xml_f="43174" txt_i="25000" txt_f="25030"> of the urinary bladder &lt; 1 cm</offsets><sup><offsets xml_i="43179" xml_f="43180" txt_i="25030" txt_f="25031">3</offsets></sup><offsets xml_i="43186" xml_f="43280" txt_i="25031" txt_f="25125">). The volume of the urethra covered by 125% of the reference dose should be smaller than 1 cm</offsets><sup><offsets xml_i="43285" xml_f="43286" txt_i="25125" txt_f="25126">3</offsets></sup><offsets xml_i="43292" xml_f="43294" txt_i="25126" txt_f="25128"> [</offsets><xref ref-type="bibr" rid="CIT0001"><offsets xml_i="43330" xml_f="43331" txt_i="25128" txt_f="25129">1</offsets></xref><offsets xml_i="43338" xml_f="43602" txt_i="25129" txt_f="25393">]. GEC/ESTRO-EUA-EORTC recommends the median target dose (MTD) in the urethra at a level of less than 120% per fraction, and below 50 Gy of the total dose on the bulb of the penis in combination therapy with EBRT + HDR-BT in order to reduce the risk of impotency [</offsets><xref ref-type="bibr" rid="CIT0004"><offsets xml_i="43638" xml_f="43639" txt_i="25393" txt_f="25394">4</offsets></xref><offsets xml_i="43646" xml_f="43648" txt_i="25394" txt_f="25396">].</offsets></p></sec><sec id="S0010"><title><offsets xml_i="43681" xml_f="43731" txt_i="25398" txt_f="25448">The comparison of temporary and permanent implants</offsets></title><p><offsets xml_i="43742" xml_f="44245" txt_i="25449" txt_f="25952">Two brachytherapy treatment modalities (LDR-BT and HDR-BT) can be only compared in monotherapy in patients with low risk tumors. In most cases, LDR-BT is administrated as a monotherapy in early detected prostate cancer. HDR-BT is usually applied along with external beam irradiation to patients with prostate tumors non qualified by strict stage terms. HDR-BT is relatively new as a monotherapy, and at the moment there are limited data about the results and the complication rates in longer follow-up [</offsets><xref ref-type="bibr" rid="CIT0016"><offsets xml_i="44281" xml_f="44283" txt_i="25952" txt_f="25954">16</offsets></xref><offsets xml_i="44290" xml_f="44292" txt_i="25954" txt_f="25956">, </offsets><xref ref-type="bibr" rid="CIT0021"><offsets xml_i="44328" xml_f="44330" txt_i="25956" txt_f="25958">21</offsets></xref><offsets xml_i="44337" xml_f="44339" txt_i="25958" txt_f="25960">, </offsets><xref ref-type="bibr" rid="CIT0038"><offsets xml_i="44375" xml_f="44377" txt_i="25960" txt_f="25962">38</offsets></xref><offsets xml_i="44384" xml_f="44386" txt_i="25962" txt_f="25964">, </offsets><xref ref-type="bibr" rid="CIT0040"><offsets xml_i="44422" xml_f="44424" txt_i="25964" txt_f="25966">40</offsets></xref><offsets xml_i="44431" xml_f="44565" txt_i="25966" txt_f="26100">]. In some publications HDR as a radiation modality has ability to deposit higher dose to the tumor and lower dose to organs at risk [</offsets><xref ref-type="bibr" rid="CIT0038"><offsets xml_i="44601" xml_f="44603" txt_i="26100" txt_f="26102">38</offsets></xref><offsets xml_i="44610" xml_f="44685" txt_i="26102" txt_f="26177">]. It produces more inhomogeneous dose distribution in the target (higher V</offsets><sub><offsets xml_i="44690" xml_f="44693" txt_i="26177" txt_f="26180">150</offsets></sub><offsets xml_i="44699" xml_f="44705" txt_i="26180" txt_f="26186"> and V</offsets><sub><offsets xml_i="44710" xml_f="44713" txt_i="26186" txt_f="26189">200</offsets></sub><offsets xml_i="44719" xml_f="44990" txt_i="26189" txt_f="26460"> parameters), but due to flexibility of planning, inhomogeneity can be used to keep the dose of organs at risk low while increase the dose on the periphery of the gland. Inhomogeneity is a cost of preserving conformality, and differs in both HDR-BT and LD-BT techniques. </offsets><xref ref-type="fig" rid="F0001"><offsets xml_i="45023" xml_f="45031" txt_i="26460" txt_f="26468">Figure 1</offsets></xref><offsets xml_i="45038" xml_f="45088" txt_i="26468" txt_f="26518"> presents differential dose volume histograms for </offsets><sup><offsets xml_i="45093" xml_f="45096" txt_i="26518" txt_f="26521">125</offsets></sup><offsets xml_i="45102" xml_f="45105" txt_i="26521" txt_f="26524">I, </offsets><sup><offsets xml_i="45110" xml_f="45113" txt_i="26524" txt_f="26527">103</offsets></sup><offsets xml_i="45119" xml_f="45126" txt_i="26527" txt_f="26534">Pd and </offsets><sup><offsets xml_i="45131" xml_f="45134" txt_i="26534" txt_f="26537">192</offsets></sup><offsets xml_i="45140" xml_f="45236" txt_i="26537" txt_f="26633">Ir from average patient-derived data. We observed heterogeneous and ‘hot’ DVH, particularly for </offsets><sup><offsets xml_i="45241" xml_f="45244" txt_i="26633" txt_f="26636">125</offsets></sup><offsets xml_i="45250" xml_f="45256" txt_i="26636" txt_f="26642">I and </offsets><sup><offsets xml_i="45261" xml_f="45264" txt_i="26642" txt_f="26645">103</offsets></sup><offsets xml_i="45270" xml_f="45274" txt_i="26645" txt_f="26649">Pd [</offsets><xref ref-type="bibr" rid="CIT0038"><offsets xml_i="45310" xml_f="45312" txt_i="26649" txt_f="26651">38</offsets></xref><offsets xml_i="45319" xml_f="45322" txt_i="26651" txt_f="26654">] (</offsets><xref ref-type="fig" rid="F0001"><offsets xml_i="45355" xml_f="45361" txt_i="26654" txt_f="26660">Fig. 1</offsets></xref><offsets xml_i="45368" xml_f="46347" txt_i="26660" txt_f="27639">). Because of impossibility to remove or adjust permanent seeds, there is no way to compensate isodose by computer planning system after implantation. Moreover, it is advisable to use high-dose rate brachytherapy in prostate cancer, suspected of extracapsular spread, in order to achieve better coverage of this area, if compared with gland only targeted seeds therapy, since the seed migration can be significant problem in this case. Apart from the dosimetry, the larger dose per fraction seems to respond better in local control of prostate cancer treatment. According to radiobiological considerations, the use of HDR-BT in these kind of tumors is far more practical. After temporary HDR-BT there are no restrictions about patients radioactivity, and possibility of seeds migration through the bloodstream outside the gland. Oedema's therapeutic dose coverage trouble does not exist in temporary implantation procedure, because of real time planning and short treatment time.</offsets></p><fig id="F0001" position="float"><label><offsets xml_i="46391" xml_f="46397" txt_i="27640" txt_f="27646">Fig. 1</offsets></label><caption><p><offsets xml_i="46417" xml_f="46464" txt_i="27646" txt_f="27693">Differential dose volume histograms (dDVH) for </offsets><sup><offsets xml_i="46469" xml_f="46472" txt_i="27693" txt_f="27696">125</offsets></sup><offsets xml_i="46478" xml_f="46481" txt_i="27696" txt_f="27699">I, </offsets><sup><offsets xml_i="46486" xml_f="46489" txt_i="27699" txt_f="27702">103</offsets></sup><offsets xml_i="46495" xml_f="46502" txt_i="27702" txt_f="27709">Pd and </offsets><sup><offsets xml_i="46507" xml_f="46510" txt_i="27709" txt_f="27712">192</offsets></sup><offsets xml_i="46516" xml_f="46572" txt_i="27712" txt_f="27768">Ir from average patient-derived data. Note that for the </offsets><sup><offsets xml_i="46577" xml_f="46580" txt_i="27768" txt_f="27771">192</offsets></sup><offsets xml_i="46586" xml_f="46772" txt_i="27771" txt_f="27957">Ir HDR brachytherapy DVH, the dose scale is ‘percent dose’, because different dose fraction sizes can be prescribed (A). Note how heterogeneous and ‘hot’ these DVH are, particularly for </offsets><sup><offsets xml_i="46777" xml_f="46780" txt_i="27957" txt_f="27960">125</offsets></sup><offsets xml_i="46786" xml_f="46792" txt_i="27960" txt_f="27966">I and </offsets><sup><offsets xml_i="46797" xml_f="46800" txt_i="27966" txt_f="27969">103</offsets></sup><offsets xml_i="46806" xml_f="46810" txt_i="27969" txt_f="27973">Pd [</offsets><xref ref-type="bibr" rid="CIT0038"><offsets xml_i="46846" xml_f="46848" txt_i="27973" txt_f="27975">38</offsets></xref><offsets xml_i="46855" xml_f="46857" txt_i="27975" txt_f="27977">]
</offsets></p></caption><graphic xlink:href="JCB-5-20569-g001"></graphic></fig><p><offsets xml_i="46929" xml_f="48010" txt_i="27978" txt_f="29059">There are also some positive aspects about using LDR-BT in radiation oncology. Patients with cancers at early stage are able to attend one day procedure in surgery with all cost profits, according to this fact. In United States, single LDR-BT costs much less than EBRT along with HDR-BT. The comparison of time duration in these two modality treatments is another serious plus point of using seeds therapy (one day versus 4-5 weeks). This technique has yet another strong argument - many cancer centers has a lot of experience in performing permanent implants, usually about 5 years longer than modern HDR-BT. Wide availability of this treatment and its frequent performing, give rise to increased number of publishing data with generally good results in treatment of organ confined prostate cancer. Seeds implants therapy, performed by experienced brachytherapist, gives almost the same quality of glands dose coverage as the temporary implants technique. One of the earliest summarized comparison of both brachytherapy techniques was presented at ASTRO Meeting in Phoenix, 1998 (</offsets><xref ref-type="table" rid="T0009"><offsets xml_i="48045" xml_f="48052" txt_i="29059" txt_f="29066">Table 9</offsets></xref><offsets xml_i="48059" xml_f="48062" txt_i="29066" txt_f="29069">).
</offsets></p><table-wrap id="T0009" position="float"><label><offsets xml_i="48113" xml_f="48120" txt_i="29070" txt_f="29077">Table 9</offsets></label><caption><p><offsets xml_i="48140" xml_f="48439" txt_i="29077" txt_f="29376">Comparison of high-dose-rate temporary implants and low-dose-rate permanent seed implants. The following table was compiled by the HDR Prostate Working Group and presented to radiation oncologists at the American Society of Therapeutic Radiology and Oncology (ASTRO) meeting in Phoenix, October 1998</offsets></p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="48586" xml_f="48600" txt_i="29377" txt_f="29391">High-dose-rate</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="48648" xml_f="48661" txt_i="29391" txt_f="29404">Low-dose-rate</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="48731" xml_f="48750" txt_i="29404" txt_f="29423">Conformal treatment</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="48798" xml_f="48802" txt_i="29424" txt_f="29428">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="48850" xml_f="48854" txt_i="29429" txt_f="29433">++++</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="48909" xml_f="48924" txt_i="29434" txt_f="29449">Target accuracy</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="48972" xml_f="48976" txt_i="29450" txt_f="29454">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49024" xml_f="49028" txt_i="29455" txt_f="29459">++++</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="49083" xml_f="49123" txt_i="29460" txt_f="29500">Ability to treat extracapsular extension</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49171" xml_f="49175" txt_i="29501" txt_f="29505">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49223" xml_f="49224" txt_i="29506" txt_f="29507">+</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="49279" xml_f="49312" txt_i="29508" txt_f="29541">Ability to treat seminal vesicles</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49360" xml_f="49364" txt_i="29542" txt_f="29546">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49412" xml_f="49414" txt_i="29547" txt_f="29549">++</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="49469" xml_f="49497" txt_i="29550" txt_f="29578">Ease of control of radiation</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49545" xml_f="49549" txt_i="29579" txt_f="29583">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49597" xml_f="49599" txt_i="29584" txt_f="29586">++</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="49654" xml_f="49676" txt_i="29587" txt_f="29609">Lack of cold/hot spots</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49724" xml_f="49728" txt_i="29610" txt_f="29614">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49776" xml_f="49778" txt_i="29615" txt_f="29617">++</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="49833" xml_f="49863" txt_i="29618" txt_f="29648">Control of critical organ dose</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49911" xml_f="49915" txt_i="29649" txt_f="29653">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="49963" xml_f="49965" txt_i="29654" txt_f="29656">++</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="50020" xml_f="50044" txt_i="29657" txt_f="29681">Modify dose distribution</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50092" xml_f="50096" txt_i="29682" txt_f="29686">++++</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50144" xml_f="50145" txt_i="29687" txt_f="29688">+</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="50200" xml_f="50222" txt_i="29689" txt_f="29711">Need for external beam</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50270" xml_f="50283" txt_i="29712" txt_f="29725">Yes/Sometimes</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50331" xml_f="50343" txt_i="29726" txt_f="29738">No/Sometimes</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="50398" xml_f="50409" txt_i="29739" txt_f="29750">Monotherapy</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50457" xml_f="50458" txt_i="29751" txt_f="29752">+</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50506" xml_f="50509" txt_i="29753" txt_f="29756">+++</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="50564" xml_f="50587" txt_i="29757" txt_f="29780">Experience of physician</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50635" xml_f="50642" txt_i="29781" txt_f="29788">Crucial</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50690" xml_f="50697" txt_i="29789" txt_f="29796">Crucial</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="50752" xml_f="50774" txt_i="29797" txt_f="29819">Pre-planning dosimetry</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50822" xml_f="50832" txt_i="29820" txt_f="29830">Not needed</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="50880" xml_f="50896" txt_i="29831" txt_f="29847">Extensive (TRUS)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="50951" xml_f="50973" txt_i="29848" txt_f="29870">Post implant dosimetry</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51021" xml_f="51031" txt_i="29871" txt_f="29881">Not needed</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51079" xml_f="51093" txt_i="29882" txt_f="29896">Extensive (CT)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="51148" xml_f="51162" txt_i="29897" txt_f="29911">Stages treated</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51210" xml_f="51220" txt_i="29912" txt_f="29922">All, T1-T3</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51268" xml_f="51273" txt_i="29923" txt_f="29928">T1-T2</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="51328" xml_f="51370" txt_i="29929" txt_f="29968">Gland volume &gt; 60 cc at time of implant</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51418" xml_f="51433" txt_i="29969" txt_f="29984">Less difficulty</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51481" xml_f="51496" txt_i="29985" txt_f="30000">More difficulty</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="51551" xml_f="51593" txt_i="30001" txt_f="30043">Pubic arch interference at time of implant</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51641" xml_f="51658" txt_i="30044" txt_f="30061">Less of a problem</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51706" xml_f="51719" txt_i="30062" txt_f="30075">Can't be done</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="51774" xml_f="51784" txt_i="30076" txt_f="30086">Prior TURP</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51832" xml_f="51849" txt_i="30087" txt_f="30104">Less of a problem</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="51897" xml_f="51917" txt_i="30105" txt_f="30125">Can't always be done</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="51972" xml_f="51995" txt_i="30126" txt_f="30149">Final Dose Verification</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="52043" xml_f="52056" txt_i="30150" txt_f="30163">Pre-treatment</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="52104" xml_f="52118" txt_i="30164" txt_f="30178">Post treatment</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="52173" xml_f="52189" txt_i="30179" txt_f="30195">Symptom duration</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="52237" xml_f="52242" txt_i="30196" txt_f="30201">Weeks</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="52290" xml_f="52296" txt_i="30202" txt_f="30208">Months</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="52351" xml_f="52363" txt_i="30209" txt_f="30221">Implant cost</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="52411" xml_f="52417" txt_i="30222" txt_f="30228">Higher</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="52465" xml_f="52470" txt_i="30229" txt_f="30234">Lower</offsets></td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions" id="S0011"><title><offsets xml_i="52561" xml_f="52572" txt_i="30236" txt_f="30247">Conclusions</offsets></title><p><offsets xml_i="52583" xml_f="53579" txt_i="30248" txt_f="31244">For the radiation treatment of prostate cancer high dose should be delivered for optimal biochemical control. Radiobiological models support the current clinical evidence for equivalent outcomes in localized prostate cancer with either LDR or HDR brachytherapy using current dose regimens. At present, the available clinical data with these two techniques suggests that they are equally effective, stage for stage, in providing high tumor control rates. Several hundred of thousands of patients have been treated with LDT-BT, with experience over 15 years and more in major centers in the US and Europe. Results are mature and well established, and mainly related to the risk group of the patient. LDR-BT has been a gold standard for prostate brachytherapy in low risk patients for many years in a lot of countries. It is a convenient technique for a patient. On the other hand HDR-BT is more cost effective with reimbursement in Eastern Europe and results for HDR monotherapy are very promising.</offsets></p><p><offsets xml_i="53586" xml_f="54053" txt_i="31245" txt_f="31709">Concluding, brachytherapy is a high, effective method of radiation dose, with higher concentration of the dose within the prostate, which affects the reduction in the risk of complications in OaRs and reduction in the frequency of complications such as impotence (5-15%) and urinary incontinence (&lt; 5%). It is also the most cost-sparing technique of all prostate cancer treatment counting all costs including diagnostic, treatment and social costs after treatment.</offsets></p></sec></body><back><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Beyer</surname><given-names>D</given-names></name><name><surname>Friedland</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1999</year><volume>44</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">10386635</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>AT</given-names></name><name><surname>Blasko</surname><given-names>JC</given-names></name><name><surname>Grimm</surname><given-names>PD</given-names></name><etal></etal></person-group><article-title>Brachytherapy for Prostate Cancer</article-title><source>Cancer J Clin</source><year>1995</year><volume>45</volume><fpage>165</fpage><lpage>178</lpage></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Garbaulet</surname><given-names>A</given-names></name><name><surname>Potter</surname><given-names>R</given-names></name><name><surname>Mazeron</surname><given-names>JJ</given-names></name><etal></etal></person-group><article-title>The GEC ESTRO Handbook of Brachytherapy</article-title><source>Brussels</source><year>2002</year><fpage>473</fpage><lpage>480</lpage><comment>chapter 20</comment></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ash</surname><given-names>D</given-names></name><name><surname>Flynn</surname><given-names>A</given-names></name><name><surname>Battermann</surname><given-names>J</given-names></name><name><surname>de Reijke</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>ESTRO/EAU/ EORTC recommendations on permanent seed implantation for localized prostate cancer</article-title><source>Radioth Oncol</source><year>2000</year><volume>57</volume><fpage>315</fpage><lpage>321</lpage></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>I</given-names></name><name><surname>Thrasher</surname><given-names>JB</given-names></name><name><surname>Aus</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Guidelines for the management of clinically localized prostate cancer: 2007 update</article-title><source>J Urol</source><year>2007</year><volume>177</volume><fpage>2106</fpage><lpage>2131</lpage><pub-id pub-id-type="pmid">17509297</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horwich</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Bangma</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2010</year><issue>Suppl 5</issue><fpage>129</fpage><lpage>133</lpage></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skowronek</surname><given-names>J</given-names></name><name><surname>Kanikowski</surname><given-names>M</given-names></name><name><surname>Zwierzchowski</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Brachyterapia LDR w leczeniu raka gruczołu krokowego</article-title><source>Wspolczesna Onkol</source><year>2009</year><volume>13</volume><fpage>316</fpage><lpage>329</lpage><comment>In Polish</comment></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohler</surname><given-names>J</given-names></name><name><surname>Bahnson</surname><given-names>RR</given-names></name><name><surname>Boston</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>NCCN clinical practice guidelines in oncology: prostate cancer</article-title><source>J Natl Compr Canc Netw</source><year>2010</year><volume>8</volume><fpage>162</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">20141676</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>P</given-names></name><name><surname>Billiet</surname><given-names>I</given-names></name><name><surname>Bostwick</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group</article-title><source>BJU Int</source><year>2012</year><volume>109</volume><issue>Suppl 1</issue><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">22239226</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>JM</given-names></name><name><surname>Gomez-Iturriaga</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>362</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">21149658</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Suarez</surname><given-names>JF</given-names></name><name><surname>Guedea</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2008</year><volume>72</volume><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">18325680</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylvester</surname><given-names>JE</given-names></name><name><surname>Grimm</surname><given-names>PD</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Fifteen-Year Biochemical Relapse-Free Survival, Cause-Specific Survival, and Overall Survival following I-125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>81</volume><fpage>376</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">20864269</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polascik</surname><given-names>TJ</given-names></name><name><surname>Pound</surname><given-names>CR</given-names></name><name><surname>DeWeese</surname><given-names>TL</given-names></name><etal></etal></person-group><article-title>Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis</article-title><source>Urology</source><year>1998</year><volume>51</volume><fpage>884</fpage><lpage>889</lpage><comment>discussion 889-90</comment><pub-id pub-id-type="pmid">9609622</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machtens</surname><given-names>S</given-names></name><name><surname>Baumann</surname><given-names>R</given-names></name><name><surname>Hagemann</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer</article-title><source>World J Urol</source><year>2006</year><volume>24</volume><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">16645877</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>G</given-names></name><name><surname>Potter</surname><given-names>R</given-names></name><name><surname>Tillmann</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localized prostate cancer</article-title><source>Radiother Oncol</source><year>2005</year><volume>74</volume><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">15734201</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burchardt</surname><given-names>W</given-names></name><name><surname>Skowronek</surname><given-names>J</given-names></name><name><surname>Łyczek</surname><given-names>J</given-names></name></person-group><article-title>Samodzielna brachyterapia HDR raka gruczołu krokowego – alternatywa we wczesnym stopniu zaawansowania</article-title><source>Przegl Urol</source><year>2012</year><volume>4</volume><fpage>33</fpage><lpage>38</lpage><comment>in Polish</comment></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chicheł</surname><given-names>A</given-names></name><name><surname>Kanikowski</surname><given-names>M</given-names></name><name><surname>Skowronek</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost</article-title><source>J Contemp Brachytherapy</source><year>2009</year><volume>1</volume><fpage>11</fpage><lpage>17</lpage></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seppenwoolde</surname><given-names>Y</given-names></name><name><surname>Kolkman-Deurloo</surname><given-names>I-K</given-names></name><name><surname>Sipkema</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>HDR prostate monotherapy – dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging</article-title><source>Radiother Oncol</source><year>2008</year><volume>86</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">18054101</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Baltas</surname><given-names>D</given-names></name><name><surname>Kurek</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study</article-title><source>Strahlenther Onkol</source><year>2004</year><volume>180</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">15057433</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galalae</surname><given-names>RM</given-names></name><name><surname>Kovacs</surname><given-names>G</given-names></name><name><surname>Schultze</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2002</year><volume>52</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">11777625</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanikowski</surname><given-names>M</given-names></name><name><surname>Skowronek</surname><given-names>J</given-names></name><name><surname>Milecki</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Brachyterapia HDR raka gruczołu krokowego</article-title><source>Urologia Polska</source><year>2007</year><volume>2</volume><fpage>5</fpage><lpage>11</lpage><comment>in Polish</comment></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chicheł</surname><given-names>A</given-names></name><name><surname>Kanikowski</surname><given-names>M</given-names></name><name><surname>Skowronek</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost</article-title><source>J Contemp Brachytherapy</source><year>2009</year><volume>1</volume><fpage>11</fpage><lpage>17</lpage></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>AA</given-names></name><name><surname>Gustafson</surname><given-names>G</given-names></name><name><surname>Gonzalez</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2002</year><volume>53</volume><fpage>316</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">12023135</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demanes</surname><given-names>DJ</given-names></name><name><surname>Rodriguez</surname><given-names>RR</given-names></name><name><surname>Altieri</surname><given-names>GA</given-names></name></person-group><article-title>High dose rate prostate brachytherapy: the California Endocurietherapy (CET) Method</article-title><source>Radiother Oncol</source><year>2000</year><volume>57</volume><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">11104888</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demanes</surname><given-names>DJ</given-names></name><name><surname>Rodriguez</surname><given-names>RR</given-names></name><name><surname>Schour</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10-year results</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>61</volume><fpage>1306</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">15817332</pub-id></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>I-C</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Vigneault</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>American Brachytherapy Society Prostate High-Dose Rate Task Group</article-title><comment>Retrieved 15-03-2010, 2010, from <ext-link ext-link-type="uri" xlink:href="http://www.americanbrachytherapy.org/guidelines/index.cfm">http://www.americanbrachytherapy.org/guidelines/index.cfm</ext-link></comment></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demanes</surname><given-names>DJ</given-names></name><name><surname>Martinez</surname><given-names>AA</given-names></name><name><surname>Ghilezan</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>High-Dose-Rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>81</volume><fpage>1286</fpage><lpage>1292</lpage><pub-id pub-id-type="pmid">21310546</pub-id></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>AA</given-names></name><name><surname>Demanes</surname><given-names>J</given-names></name><name><surname>Vargas</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer</article-title><source>Am J Clin Oncol</source><year>2010</year><volume>33</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">19952715</pub-id></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>L</given-names></name><name><surname>Rogers</surname><given-names>LI</given-names></name></person-group><article-title>Extended follow up of high-dose-rate brachytherapy as monotherapy for intermediate- risk prostate cancer</article-title><source>Brachytherapy</source><year>2010</year><volume>9</volume><issue>Suppl. 1</issue><fpage>S55</fpage><lpage>S56</lpage></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Konishi</surname><given-names>K</given-names></name><name><surname>Oh</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer</article-title><source>Radiother Oncol</source><year>2006</year><volume>80</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">16870289</pub-id></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Konishi</surname><given-names>K</given-names></name><name><surname>Sumida</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Monotherapeutic High-Dose-Rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>80</volume><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">20646858</pub-id></element-citation></ref><ref id="CIT0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>AA</given-names></name><name><surname>Pataki</surname><given-names>I</given-names></name><name><surname>Edmundson</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2001</year><volume>49</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">11163498</pub-id></element-citation></ref><ref id="CIT0033"><label>33</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Merrick</surname><given-names>GS</given-names></name><name><surname>Zelefsky</surname><given-names>M</given-names></name><name><surname>Sylvester</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>American Brachytherapy Society Prostate Low-Dose Rate Task Group</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://www.americanbrachytherapy.org/guidelines/prostate_low-doseratetaskgroup.pdf">http://www.americanbrachytherapy.org/guidelines/prostate_low-doseratetaskgroup.pdf</ext-link></comment></element-citation></ref><ref id="CIT0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrick</surname><given-names>GS</given-names></name><name><surname>Butler</surname><given-names>WM</given-names></name><name><surname>Galbreath</surname><given-names>RW</given-names></name><etal></etal></person-group><article-title>Biochemical outcome for hormone-naive patients with Gleason score 3 + 4 versus 4 + 3 prostate cancer undergoing permanent prostate brachytherapy</article-title><source>Urology</source><year>2002</year><volume>60</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">12100932</pub-id></element-citation></ref><ref id="CIT0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallner</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Wasserman</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1997</year><volume>37</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">9112454</pub-id></element-citation></ref><ref id="CIT0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WR</given-names></name></person-group><article-title>The role of androgen deprivation therapy combined with prostate brachytherapy</article-title><source>Urology</source><year>2002</year><volume>60</volume><issue>3 Suppl 1</issue><fpage>39</fpage><lpage>44</lpage><comment>discussion 44</comment></element-citation></ref><ref id="CIT0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujades Ma</surname><given-names>C</given-names></name><name><surname>Camacho</surname><given-names>C</given-names></name><name><surname>Perez-Calatayud</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>The use of nomograms in LDR-HDR prostate brachytherapy</article-title><source>J Contemp Brachytherapy</source><year>2011</year><volume>3</volume><fpage>121</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">23346120</pub-id></element-citation></ref><ref id="CIT0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>CR</given-names></name></person-group><article-title>LDR vs HDR brachytherapy for localized prostate cancer- the view from radiobiological models</article-title><source>Brachytherapy</source><year>2002</year><volume>1</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">15062170</pub-id></element-citation></ref><ref id="CIT0039"><label>39</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Leibel</surname><given-names>SA</given-names></name><name><surname>Phillips</surname><given-names>TL</given-names></name></person-group><source>Textbook of Radiation Oncology</source><year>2004</year><edition>Second Edition</edition><fpage>988</fpage><lpage>1000</lpage><comment>Chapter 45</comment></element-citation></ref><ref id="CIT0040"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grills</surname><given-names>IS</given-names></name><name><surname>Martinez</surname><given-names>AA</given-names></name><name><surname>Hollander</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds</article-title><source>J Urol</source><year>2004</year><volume>171</volume><fpage>1098</fpage><lpage>1104</lpage><pub-id pub-id-type="pmid">14767279</pub-id></element-citation></ref></ref-list></back></article>